NZ624442B2 - Responsiveness to angiogenesis inhibitors - Google Patents
Responsiveness to angiogenesis inhibitors Download PDFInfo
- Publication number
- NZ624442B2 NZ624442B2 NZ624442A NZ62444212A NZ624442B2 NZ 624442 B2 NZ624442 B2 NZ 624442B2 NZ 624442 A NZ624442 A NZ 624442A NZ 62444212 A NZ62444212 A NZ 62444212A NZ 624442 B2 NZ624442 B2 NZ 624442B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancer
- patient
- bevacizumab
- snp
- genotype
- Prior art date
Links
- 239000004037 angiogenesis inhibitor Substances 0.000 title claims abstract description 46
- 229940121369 angiogenesis inhibitors Drugs 0.000 title claims abstract description 45
- 230000004043 responsiveness Effects 0.000 title description 2
- 108010005144 Bevacizumab Proteins 0.000 claims abstract description 98
- 229960000397 bevacizumab Drugs 0.000 claims abstract description 98
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims abstract description 73
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims abstract description 46
- 108020004705 Codon Proteins 0.000 claims abstract description 45
- 201000011510 cancer Diseases 0.000 claims abstract description 44
- 230000001965 increased Effects 0.000 claims abstract description 40
- 108090001123 antibodies Proteins 0.000 claims abstract description 33
- 102000004965 antibodies Human genes 0.000 claims abstract description 33
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 32
- 229940014598 TAC Drugs 0.000 claims abstract description 26
- 230000000875 corresponding Effects 0.000 claims abstract description 15
- 230000001575 pathological Effects 0.000 claims abstract description 15
- 230000002491 angiogenic Effects 0.000 claims abstract description 13
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims abstract description 11
- 238000000338 in vitro Methods 0.000 claims abstract description 10
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims abstract 7
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 claims abstract 4
- 230000000694 effects Effects 0.000 claims description 25
- 239000002246 antineoplastic agent Substances 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 230000004083 survival Effects 0.000 claims description 19
- 230000033115 angiogenesis Effects 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 9
- 238000009104 chemotherapy regimen Methods 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 8
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 7
- 229960002949 Fluorouracil Drugs 0.000 claims description 7
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 7
- 102000006992 Interferon-alpha Human genes 0.000 claims description 7
- 108010047761 Interferon-alpha Proteins 0.000 claims description 7
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims description 7
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 7
- 235000008191 folinic acid Nutrition 0.000 claims description 7
- 239000011672 folinic acid Substances 0.000 claims description 7
- 229960005277 gemcitabine Drugs 0.000 claims description 7
- 229960001691 leucovorin Drugs 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 6
- 229960004117 Capecitabine Drugs 0.000 claims description 6
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 6
- 229960001433 Erlotinib Drugs 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 238000007792 addition Methods 0.000 claims description 4
- 229940045698 antineoplastic Taxanes Drugs 0.000 claims description 4
- 201000011231 colorectal cancer Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229910052697 platinum Inorganic materials 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 101710034857 ATIC Proteins 0.000 claims description 3
- 241000897276 Termes Species 0.000 claims 1
- 239000000523 sample Substances 0.000 description 72
- 102100006565 FLT1 Human genes 0.000 description 71
- 102100015249 VEGFA Human genes 0.000 description 41
- 229920000272 Oligonucleotide Polymers 0.000 description 34
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 33
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 29
- 230000003321 amplification Effects 0.000 description 26
- 238000003199 nucleic acid amplification method Methods 0.000 description 26
- 238000009396 hybridization Methods 0.000 description 25
- 150000007523 nucleic acids Chemical class 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 21
- 239000002773 nucleotide Substances 0.000 description 21
- 125000003729 nucleotide group Chemical group 0.000 description 21
- 238000004166 bioassay Methods 0.000 description 20
- 108020004707 nucleic acids Proteins 0.000 description 20
- 210000004027 cells Anatomy 0.000 description 18
- 238000001514 detection method Methods 0.000 description 18
- 229940058140 Avita Drugs 0.000 description 17
- 239000011717 all-trans-retinol Substances 0.000 description 17
- 235000019169 all-trans-retinol Nutrition 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 17
- 239000000969 carrier Substances 0.000 description 14
- 230000000295 complement Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 230000027455 binding Effects 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- 230000002068 genetic Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 102100012897 PGF Human genes 0.000 description 10
- 108010082093 Placenta Growth Factor Proteins 0.000 description 10
- 239000000090 biomarker Substances 0.000 description 10
- -1 busulfan) Chemical class 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 229940068196 placebo Drugs 0.000 description 10
- 239000000902 placebo Substances 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 229940120638 Avastin Drugs 0.000 description 8
- 102100013180 KDR Human genes 0.000 description 8
- 206010061289 Metastatic neoplasm Diseases 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 229920002676 Complementary DNA Polymers 0.000 description 7
- 108020004999 Messenger RNA Proteins 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 229920002106 messenger RNA Polymers 0.000 description 7
- 230000001394 metastastic Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000002194 synthesizing Effects 0.000 description 7
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 6
- 210000004369 Blood Anatomy 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 229960001592 Paclitaxel Drugs 0.000 description 6
- 210000002381 Plasma Anatomy 0.000 description 6
- 229920001949 Transfer RNA Polymers 0.000 description 6
- 108020004566 Transfer RNA Proteins 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 229960001756 oxaliplatin Drugs 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229930003347 taxol Natural products 0.000 description 6
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 5
- 206010038389 Renal cancer Diseases 0.000 description 5
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 201000010982 kidney cancer Diseases 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- KKZRPIKZBFQAKR-YPWTWYSKSA-N 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1.C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 KKZRPIKZBFQAKR-YPWTWYSKSA-N 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 4
- 229960004562 Carboplatin Drugs 0.000 description 4
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 4
- 101700011961 DPOM Proteins 0.000 description 4
- 229940088598 Enzyme Drugs 0.000 description 4
- 229960003521 Interferon Alfa-2a Drugs 0.000 description 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 4
- 101710029649 MDV043 Proteins 0.000 description 4
- 206010027476 Metastasis Diseases 0.000 description 4
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 4
- 101700061424 POLB Proteins 0.000 description 4
- 101700054624 RF1 Proteins 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000002596 correlated Effects 0.000 description 4
- 230000004059 degradation Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000001809 detectable Effects 0.000 description 4
- 229960004768 irinotecan Drugs 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 4
- 239000002751 oligonucleotide probe Substances 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 210000004204 Blood Vessels Anatomy 0.000 description 3
- 108010014064 CCCTC-Binding Factor Proteins 0.000 description 3
- 102100011221 CTCFL Human genes 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- 108091007936 ERK family Proteins 0.000 description 3
- 206010017758 Gastric cancer Diseases 0.000 description 3
- 208000005017 Glioblastoma Diseases 0.000 description 3
- 101710030888 KDR Proteins 0.000 description 3
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 3
- 229920001850 Nucleic acid sequence Polymers 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000036823 Plasma Levels Effects 0.000 description 3
- 102100015205 VEGFD Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000005251 capillar electrophoresis Methods 0.000 description 3
- 201000009030 carcinoma Diseases 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000003211 malignant Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920000023 polynucleotide Polymers 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000002829 reduced Effects 0.000 description 3
- 238000000611 regression analysis Methods 0.000 description 3
- 230000000391 smoking Effects 0.000 description 3
- 108010068698 spleen exonuclease Proteins 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 3
- 238000004450 types of analysis Methods 0.000 description 3
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 2
- OMJKFYKNWZZKTK-UXBLZVDNSA-N (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1\N=CN=C1C(N)=O OMJKFYKNWZZKTK-UXBLZVDNSA-N 0.000 description 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 2
- IRLPACMLTUPBCL-KQYNXXCUSA-N 5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](O)[C@H]1O IRLPACMLTUPBCL-KQYNXXCUSA-N 0.000 description 2
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2S)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 2
- 206010064930 Age-related macular degeneration Diseases 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N Aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 229960003437 Aminoglutethimide Drugs 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 102000025380 C-Reactive Protein Human genes 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 2
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 229920001405 Coding region Polymers 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 108010007730 EC 3.6.1.5 Proteins 0.000 description 2
- 102000007347 EC 3.6.1.5 Human genes 0.000 description 2
- 102100019027 EGLN1 Human genes 0.000 description 2
- 101700036086 EGLN1 Proteins 0.000 description 2
- 229920000665 Exon Polymers 0.000 description 2
- 101710030892 FLT1 Proteins 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 102100003042 HIF1A Human genes 0.000 description 2
- 241000282619 Hylobates lar Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 2
- 101700033678 KDR Proteins 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 108060001084 Luciferase family Proteins 0.000 description 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
- 101700003847 MSN1 Proteins 0.000 description 2
- 208000002780 Macular Degeneration Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920002393 Microsatellite Polymers 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229960001156 Mitoxantrone Drugs 0.000 description 2
- HDZGCSFEDULWCS-UHFFFAOYSA-N Monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 2
- 210000000440 Neutrophils Anatomy 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 229960003171 Plicamycin Drugs 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J Pyrophosphate Chemical group [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 206010038038 Rectal cancer Diseases 0.000 description 2
- 229920001914 Ribonucleotide Polymers 0.000 description 2
- 241000239226 Scorpiones Species 0.000 description 2
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 2
- 102000004523 Sulfate Adenylyltransferase Human genes 0.000 description 2
- 108010022348 Sulfate Adenylyltransferase Proteins 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 229940035295 Ting Drugs 0.000 description 2
- 101700068732 VEGFA Proteins 0.000 description 2
- 102100015207 VEGFB Human genes 0.000 description 2
- 102100015206 VEGFC Human genes 0.000 description 2
- 102100014859 VHL Human genes 0.000 description 2
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 2
- 229950000578 Vatalanib Drugs 0.000 description 2
- YCOYDOIWSSHVCK-UHFFFAOYSA-N Vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 2
- 108010030337 Von Hippel-Lindau Tumor Suppressor Protein Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive Effects 0.000 description 2
- 230000003042 antagnostic Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000002349 favourable Effects 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- 230000037266 fold induction Effects 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960003407 pegaptanib Drugs 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000000092 prognostic biomarker Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching Effects 0.000 description 2
- 230000002285 radioactive Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 229960003440 semustine Drugs 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N 10294-56-1 Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N 17-Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-N-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- 108060005293 AGA Proteins 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 1
- 229940030486 ANDROGENS Drugs 0.000 description 1
- 229940030495 ANTIANDROGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 description 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 1
- 102100004323 ASPG Human genes 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 229940045714 Alkyl sulfonate alkylating agents Drugs 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 229940046836 Anti-estrogens Drugs 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 108020005098 Anticodon Proteins 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229960002756 Azacitidine Drugs 0.000 description 1
- 229960002170 Azathioprine Drugs 0.000 description 1
- 208000003950 B-Cell Lymphoma Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- OYVAGSVQBOHSSS-WXFSZRTFSA-O Bleomycin Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-WXFSZRTFSA-O 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- FVLVBPDQNARYJU-KYZUINATSA-N CHEMBL1967746 Chemical compound C[C@H]1CC[C@H](NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-KYZUINATSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 206010008943 Chronic leukaemia Diseases 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229960000684 Cytarabine Drugs 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N Diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 1
- 101700074107 EFH1 Proteins 0.000 description 1
- 101700033006 EGF Proteins 0.000 description 1
- 102100010813 EGF Human genes 0.000 description 1
- 102100009701 EGLN2 Human genes 0.000 description 1
- 101700051198 EGLN2 Proteins 0.000 description 1
- 102100009704 EGLN3 Human genes 0.000 description 1
- 101700053907 EGLN3 Proteins 0.000 description 1
- 102100016168 EPAS1 Human genes 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- 101700025368 ERBB2 Proteins 0.000 description 1
- 102100016662 ERBB2 Human genes 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 210000002889 Endothelial Cells Anatomy 0.000 description 1
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 229960001842 Estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 241000188455 Eurybia avita Species 0.000 description 1
- 208000009745 Eye Disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960001751 Fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N Fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 206010018001 Gastrointestinal perforation Diseases 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 210000004907 Glands Anatomy 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 101700000053 HIF1A Proteins 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- 229920001681 Heteroduplex Polymers 0.000 description 1
- 102000003893 Histone Acetyltransferases Human genes 0.000 description 1
- 108090000246 Histone Acetyltransferases Proteins 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000002177 Hypoxia-inducible factor-1 alpha Human genes 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 108090000745 Immune Sera Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 229920002459 Intron Polymers 0.000 description 1
- 108020004391 Introns Proteins 0.000 description 1
- 206010061255 Ischaemia Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 229940008250 Leuprolide Drugs 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229960004338 Leuprorelin Drugs 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101700083887 MAPK1 Proteins 0.000 description 1
- 102100016823 MAPK1 Human genes 0.000 description 1
- 206010026798 Mantle cell lymphomas Diseases 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- 208000006395 Meigs Syndrome Diseases 0.000 description 1
- 206010027139 Meigs' syndrome Diseases 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108020004388 MicroRNAs Proteins 0.000 description 1
- 229960000350 Mitotane Drugs 0.000 description 1
- 206010028549 Myeloid leukaemia Diseases 0.000 description 1
- 101700080605 NUC1 Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000000919 Neurocutaneous Syndrome Diseases 0.000 description 1
- 101710003000 ORF1/ORF2 Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 229960002340 Pentostatin Drugs 0.000 description 1
- 206010034576 Peripheral ischaemia Diseases 0.000 description 1
- 229940072417 Peroxidase Drugs 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108090000437 Peroxidases Proteins 0.000 description 1
- 206010051358 Post transplant lymphoproliferative disease Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 210000003705 Ribosomes Anatomy 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108009000491 Small cell lung cancer Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920002541 TRNADB Polymers 0.000 description 1
- 101700083672 TUP1 Proteins 0.000 description 1
- 229960001603 Tamoxifen Drugs 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- 229960001712 Testosterone Propionate Drugs 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 229960005454 Thioguanine Drugs 0.000 description 1
- 229960001196 Thiotepa Drugs 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 108010010691 Trastuzumab Proteins 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N Trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 Trimetrexate Drugs 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010046766 Uterine cancer Diseases 0.000 description 1
- 108091007928 VEGF receptors Proteins 0.000 description 1
- 101700070240 VEGFB Proteins 0.000 description 1
- 101700082383 VEGFC Proteins 0.000 description 1
- 101700020875 VEGFD Proteins 0.000 description 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- 206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 235000019395 ammonium persulphate Nutrition 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic Effects 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000118 anti-eoplastic Effects 0.000 description 1
- 230000001833 anti-estrogenic Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- 229940045719 antineoplastic alkylating agents Nitrosoureas Drugs 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 230000002238 attenuated Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000000740 bleeding Effects 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 201000006474 brain ischemia Diseases 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 230000002604 chemotoxic Effects 0.000 description 1
- 231100000196 chemotoxic Toxicity 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001447 compensatory Effects 0.000 description 1
- 229920000407 conserved sequence Polymers 0.000 description 1
- 230000001054 cortical Effects 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000000593 degrading Effects 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000464 effect on transcription Effects 0.000 description 1
- 230000000463 effect on translation Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 201000009273 endometriosis Diseases 0.000 description 1
- 230000003511 endothelial Effects 0.000 description 1
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 101710024775 erkB Proteins 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 238000003260 fluorescence intensity Methods 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical class C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000003783 haploid cell Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 230000001146 hypoxic Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000000984 immunochemical Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000000527 lymphocytic Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-L methylphosphonate(2-) Chemical class CP([O-])([O-])=O YACKEPLHDIMKIO-UHFFFAOYSA-L 0.000 description 1
- 229920001239 microRNA Polymers 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000001617 migratory Effects 0.000 description 1
- 230000002297 mitogenic Effects 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000005445 natural product Substances 0.000 description 1
- 229930014626 natural products Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003956 nonsteroidal anti androgen Substances 0.000 description 1
- 101700006494 nucA Proteins 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 230000003285 pharmacodynamic Effects 0.000 description 1
- 101700056794 phd1 Proteins 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 108091005965 phosphorylated proteins Proteins 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000001023 pro-angiogenic Effects 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- FVLVBPDQNARYJU-UHFFFAOYSA-N semustine Chemical compound CC1CCC(NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 230000000392 somatic Effects 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000153 supplemental Effects 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108090000464 transcription factors Proteins 0.000 description 1
- 102000003995 transcription factors Human genes 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000989 vascularization Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 208000006542 von Hippel-Lindau Disease Diseases 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
Disclosed is an in vitro method of determining whether a patient suffering from cancer or physiological or pathological angiogenic abnormalities is suitably treated by a therapy with an angiogenesis inhibitor comprising bevacizumab or an antibody that binds essentially the same epitope on VEGF as bevacizumab, said method comprising: (a) determining in a sample derived from a patient suffering from cancer or physiological or pathological angiogenic abnormalities the genotype at the synonymous T/C SNP located in exon 28 of VEGFR-1 corresponding respectively to TAT codon and TAC codon for tyrosine at position 1213, and (b) identifying said patient as more or less suitably treated by a therapy with an angiogenesis inhibitor comprising bevacizumab or an antibody that binds essentially the same epitope on VEGF as bevacizumab based on said genotype, wherein the presence of each T allele at said SNP indicates an increased likelihood that the patient is more suitably treated, or the presence of each C allele at said SNP indicates an increased likelihood that the patient is less suitably treated. vacizumab, said method comprising: (a) determining in a sample derived from a patient suffering from cancer or physiological or pathological angiogenic abnormalities the genotype at the synonymous T/C SNP located in exon 28 of VEGFR-1 corresponding respectively to TAT codon and TAC codon for tyrosine at position 1213, and (b) identifying said patient as more or less suitably treated by a therapy with an angiogenesis inhibitor comprising bevacizumab or an antibody that binds essentially the same epitope on VEGF as bevacizumab based on said genotype, wherein the presence of each T allele at said SNP indicates an increased likelihood that the patient is more suitably treated, or the presence of each C allele at said SNP indicates an increased likelihood that the patient is less suitably treated.
Description
Case 30723
siveness to enesis Inhibitors
Field of the Invention
The t invention is directed to methods for fying which patients will most benefit
from ent with anti-cancer agents and monitoring patients for their sensitivity and
responsiveness to treatment with ancer agents.
Background of the Invention
Angiogenesis contributes to benign and malignant diseases such as cancer development and,
especially in cancer, is necessary for primary tumor growth, invasiveness and metastasis. In
order to grow, a tumor must undergo an angiogenic switch. Vascular endothelial growth factor
(VEGF) is required to induce this angiogenic . VEGF and the genes in the VEGF pathway
are considered important ors of cancer progression. The VEGF gene family includes the
VEGF gene, also referred to as VEGFA, homologues to VEGF including, placenta growth factor
(PlGF), VEGFB, VEGFC, VEGFD, the VEGF receptors, including VEGFR-1 and VEGFR-2
(also referred to as FLT1 and FLK1/KDR, respectively), the VEGF inducers, including hypoxiainducible
s HIF1α, HIF2 α, and the oxygen sensors PHD1, PHD2 and PHD3.
The importance of this pathway in cancer cell growth and metastasis has led to the development
of anti-angiogenesis agents for use in cancer therapy. These therapies include, among others,
bevacizumab, pegaptanib, sunitinib, sorafenib and vatalanib. Despite significantly prolonged
survival obtained with angiogenesis inhibitors, such as bevacizumab, patients still succumb to
cancer. Further, not all patients respond to angiogenesis inhibitor therapy. The mechanism
underlying the sponsiveness remains unknown. Moreover, angiogenesis inhibitor therapy
is associated with side effects, such as gastrointestinal perforation, thrombosis, bleeding,
hypertension and proteinuria.
AOK / 30.08.2012
Accordingly, there is a need for methods of determining which patients respond particular well
to angiogenesis inhibitor therapy.
It has been described in WO 15348 that one or more t alleles of the VEGFR-1 gene
are associated with improved outcome of the anti-angiogenesis treatment. Among the SNPs
disclosed in are rs9554316, rs9582036, rs9513070 and rs9554320, while other
SNPs are fied by linkage disequilibrium and therfore linked to these four SNPs.
Summary of the Invention
It has been found that one of the SNPs identified by linkage disequilibrium and disclosed in WO
2011/015348 is particularly useful as a predictive ker for the treatment outcome of an
angiogenesis inhibitor, such as bevacizumab.
The present invention therefore s to a method of determining whether a patient is more or
less suitably d by a therapy with an angiogenesis inhibitor, such as bevacizumab, by
determing the pe at the synonymous T/C SNP located in exon 28 of VEGFR-1
corresponding respectively to TAT codon and TAC codon for tyrosine at position 1213. The
present invention also relates to the use of a pharmaceutical ition comprising
bevacizumab, for the ation of a medicament for treatment of a patient suffering from
cancer and having the genotype associated with an improved treatment effect at the synonymous
T/C SNP located in exon 28 of VEGFR-1 corresponding respectively to TAT codon and TAC
codon for tyrosine at position 1213. Also described herein is a method for improving the
treatment effect of chemotherapy of a patient suffering from cancer by adding an enesis
inhibitor, such as bevacizumab, based on the genotype at the synonymous T/C SNP located in
exon 28 of VEGFR-1 corresponding tively to TAT codon and TAC codon for tyrosine at
on 1213.
In another embodiment, the invention relates to the use of an angiogenesis inhibitor
comprising bevacizumab or an antibody that binds essentially the same epitope on VEGF as
bevacizumab for the preparation of a medicament for improving the treatment effect of a
chemotherapeutic agent or chemotherapy regimen of a patient suffering from cancer or
physiological or pathological enic abnormalities, wherein the patient has been identified
by a method comprising:
(a) determining in a sample derived from a patient suffering from cancer or physiological
or pathological angiogenic abnormalities the genotype at the synonymous T/C SNP located in
exon 28 of VEGFR-1 corresponding respectively to TAT codon and TAC codon for tyrosine at
position 1213; and
(b) fying said patient as more suitably treated by the addition of an angiogenesis
inhibitor comprising zumab or an antibody that binds essentially the same epitope on
VEGF as bevacizumab based on said genotype, wherein the presence of each T allele at said
SNP indicates an increased likelihood that the patient is more suitably treated.
Detailed Description of the ments
1. Definitions
The term "administering" means the administration of a pharmaceutical composition, such as an
enesis inhibitor, to the patient. For example, 2.5 mg/kg of body weight to 15 mg/kg of
body weight bevacizumab (Avastin®) can be administered every week, every 2 weeks or every 3
weeks, depending on the type of cancer being treated. Particular dosages include 5 mg/kg, 7.5
mg/kg, 10 mg/kg and 15 mg/kg. Even more particular dosages are 5 mg/kg every 2 weeks, 10
mg/kg every 2 weeks and 15 mg/kg every 3 weeks.
The term "angiogenesis inhibitor" in the context of the present invention refers to all agents that
alter enesis (e.g. the process of forming blood vessels) and includes agents that inhibit the
angiogenesis, including, but not limited to, tumor angiogenesis. In this context, inhibition can
refer to blocking the ion of blood vessels and halting or slowing down the growth of blood
vessels. Examples of angiogenesis tors include bevacizumab (also known as Avastin®),
pegaptanib, sunitinib, nib and vatalanib. Bevacizumab is a recombinant humanized
monoclonal IgG1 antibody that binds to and inhibits the biological activity of human VEGFA in
in vitro and in vivo assay system. The term "bevacizumab" encompass all corresponding anti-
VEGF antibodies that fulfill the requirements necessary for ing a marketing authorization
as an cal or biosimilar product in a country or ory selected from the group of countries
consisting of the USA, Europe and Japan. In the context of the present invention, an
angiogenesis inhibitor includes an antibody that binds essentially the same epitope on VEGF as
bevacizumab, more specifically an antibody that binds to the same e on VEGF as
bevacizumab. An antibody binds "essentially the same e" as a reference antibody, when
the two antibodies recognize identical or sterically overlapping epitopes. The most widely used
and rapid methods for determining whether two epitopes bind to identical or sterically
overlapping epitopes are competition assays, which can be configured in all number of different
formats, using either labeled n or labeled antibody. Usually, the antigen is immobilized on
a 96-well plate, and the ability of unlabeled antibodies to block the binding of labeled antibodies
is measured using radioactive or enzyme labels.
The term “cancer” refers to the physiological condition in mammals that is typically
terized by unregulated cell eration. Examples of cancer include but are not limited to,
carcinoma, lymphoma, blastoma, sarcoma and leukemia. More particular examples of such
cancers include squamous cell cancer, lung cancer (including small-cell lung cancer, all
cell lung cancer, arcinoma of the lung, and squamous carcinoma of the lung), cancer of
the neum, hepatocellular cancer, gastric or stomach cancer (including intestinal
cancer), pancreatic cancer (including ic pancreatic cancer), glioblastoma, cervical cancer,
ovarian cancer, liver , bladder cancer, hepatoma, breast cancer (including locally advanced,
recurrent or metastatic HER-2 negative breast cancer), colon cancer, colorectal cancer,
endometrial or uterine carcinoma, ry gland carcinoma, kidney or renal cancer, liver ,
prostate cancer, vulval , thyroid cancer, hepatic carcinoma and various types of head and
neck cancer, as well as B-cell lymphoma (including low grade/follicular non-Hodgkin's
lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade/follicular NHL;
intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic
NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma;
AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia); chronic lymphocytic
leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell ia; chronic
myeloblastic leukemia; and post-transplant lymphoproliferative disorder , as well as
abnormal vascular proliferation associated with phakomatoses, edema (such as that associated
with brain tumors), and Meigs' syndrome.
Examples of ological or pathological angiogenic abnormalities” include, but are not
limited to, eye disease such as age-related macular degeneration (AMD), high grade glioma,
glioblastoma, M. Rendu-Osler, von-Hippel-Lindau diseases, iomas, psoriasis, Kaposi's
a, ocular neovascularisation, rheumatoid arthritis, endometriosis, atherosclerosis,
myochardial ischemia, peripheral ischemia, cerebral ischemia and wound healing.
The term "chemotherapeutic agent" or therapy regimen" includes any active agent that
can provide an anticancer therapeutic effect and may be a chemical agent or a biological agent,
in particular, that are capable of interfering with cancer or tumor cells. Particular active agents
are those that act as anti-neoplastic (chemotoxic or chemostatic) agents which inhibit or prevent
the development, maturation or proliferation of malignant cells. Examples of chemotherapeutic
agents include alkylating agents such as nitrogen mustards (e.g., mechlorethamine,
cyclophosphamide, ifosfamide, melphalan and chlorambucil), nitrosoureas (e.g., carmustine
(BCNU), lomustine (CCNU), and semustine (methyl-CCNU)), ethylenimines/ methylmelamines
(e.g., thriethylenemelamine (TEM), triethylene, thiophosphoramide (thiotepa),
thylmelamine (HMM, altretamine)), alkyl sulfonates (e.g., busulfan), and triazines (e.g.,
dacarbazine (DTIC)); antimetabolites such as folic acid analogs (e.g., methotrexate, trimetrexate),
pyrimidine analogs (e.g., 5-fluorouracil, capecitabine, fluorodeoxyuridine, gemcitabine, cytosine
arabinoside (AraC, cytarabine), 5-azacytidine, 2,2′-difluorodeoxycytidine), and purine analogs
(e.g., aptopurine, 6-thioguanine, azathioprine, 2′-deoxycoformycin (pentostatin),
erythrohydroxynonyladenine (EHNA), fludarabine phosphate, and rodeoxyadenosine
(cladribine, 2-CdA)); antimitotic drugs developed from natural products (e.g., paclitaxel, vinca
alkaloids (e.g., vinblastine (VLB), vincristine, and vinorelbine), docetaxel, estramustine, and
ustine phosphate), epipodophylotoxins (.e.g., etoposide, teniposide), antibiotics (.e.g,
actimomycin D, daunomycin omycin), daunorubicon, bicin, epirubicin,
mitoxantrone, idarubicin, bleomycins, plicamycin (mithramycin), mitomycinC, actinomycin),
enzymes (e.g., L-asparaginase), and biological se modifiers (e.g., interferon-alpha, IL-2,
G-CSF, GM-CSF); miscellaneous agents including platinum coordination complexes (e.g.,
cisplatin, carboplatin, oxaliplatin), anthracenediones (e.g., mitoxantrone), substituted urea (i.e.,
hydroxyurea), hydrazine derivatives (e.g., N-methylhydrazine (MIH), procarbazine),
cortical suppressants (e.g., mitotane (o,p′-DDD), aminoglutethimide); hormones and
antagonists including adrenocorticosteroid antagonists (.e.g, sone and lents,
dexamethasone, aminoglutethimide), progestins (e.g., hydroxyprogesterone caproate,
medroxyprogesterone acetate, rol acetate), ens (e.g., diethylstilbestrol, ethinyl
iol and equivalents thereof); antiestrogens (e.g., tamoxifen), androgens (e.g., testosterone
propionate, fluoxymesterone and equivalents f), antiandrogens (e.g., flutamide,
gonadotropin-releasing hormone analogs, leuprolide), non-steroidal antiandrogens (e.g.,
flutamide), epidermal growth factor inhibitors (e.g., erlotinib, lapatinib, gefitinib) antibodies (e.g.,
trastuzumab), irinotecan and other agents such as leucovorin. For the treatment of metastatic
pancreatic cancer, chemotherapeutic agents for administration with bevacizumab include
gemcitabine and erlotinib and combinations thereof (see also the examples herein ed). For
the treatment of renal cell cancer, chemotherapeutic agents for administration with bevacizumab
include eron alpha (see also the examples herein provided).
The term “allele” refers to a nucleotide sequence t of a gene of interest.
The term “genotype” refers to a description of the s of a gene contained in an individual or
a sample. In the context of this invention, no distinction is made between the genotype of an
individual and the genotype of a sample originating from the individual. Although typically a
genotype is ined from samples of diploid cells, a genotype can be determined from a
sample of haploid cells, such as a sperm cell.
The terms nucleotide" and "polynucleotide" are used interchangeably and refer to a
molecule comprised of two or more deoxyribonucleotides or ribonucleotides, preferably more
than three. Its exact size will depend on many factors, which in turn depend on the ultimate
function or use of the oligonucleotide. An oligonucleotide can be derived synthetically or by
g. as of deoxyribonucleotides and ribonucleotides may also be in the scope of the
present invention.
The term “polymorphism” refers to the occurrence of two or more genetically determined
alternative sequences of a gene in a population. Typically, the first identified allelic form is
arbitrarily designated as the nce form and other allelic forms are designated as alternative
or variant alleles. The allelic form occurring most frequently in a selected population is
sometimes referred to as the wildtype form.
The term a “single nucleotide polymorphism” or “SNP” is a site of one nucleotide that varies
n alleles. Single tide polymorphisms may occur at any region of the gene. In some
instances the polymorphism can result in a change in protein sequence. The change in protein
sequence may affect protein function or not.
The term "patient" refers to any single , more specifically a mammal (including such non-
human animals as, for example, dogs, cats, horses, rabbits, zoo animals, cows, pigs, sheep, and
non-human primates) for which treatment is desired. Even more specifically, the patient herein is
a human. In the context of the present invention, the patient may be Caucasian.
The term “subject” herein is any single human subject, including a t, eligible for treatment
who is experiencing or has experienced one or more signs, symptoms, or other indicators of an
angiogenic disorder. Intended to be included as a subject are any ts involved in clinical
research trials not showing any clinical sign of disease, or subjects involved in epidemiological
studies, or subjects once used as controls. The subject may have been previously treated with an
anti-cancer agent, or not so treated. The subject may be naïve to an additional agent(s) being
used when the treatment herein is started, i.e., the subject may not have been previously treated
with, for example, an anti-neoplastic agent, a chemotherapeutic agent, a growth inhibitory agent,
a cytotoxic agent at “baseline” (i.e., at a set point in time before the administration of a first dose
of an anti-cancer in the ent method herein, such as the day of ing the subject before
treatment is commenced). Such "naïve" subjects are generally considered to be candidates for
treatment with such additional agent(s).
The term "a patient ing from" refers to a patient showing clinical signs in respect to a
certain ant e, such as cancer, a e involving physiological and pathological
angiogenesis and/or tumorous disease.
As used herein, “therapy” or “treatment” refers to clinical intervention in an attempt to alter the
l course of the individual or cell being treated, and can be performed either for prophylaxis
or during the course of al pathology. Desirable effects of treatment include preventing
occurrence or recurrence of disease, alleviation of symptoms, shment of any direct or
indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of
disease progression, amelioration or palliation of the disease state, and remission or improved
prognosis.
The term "treatment effect" encompasses the terms "overall survival" and "progression-free
survival".
The term "overall survival" refers to the length of time during and after treatment the t
survives. As the skilled person will appreciate, a patient's overall survival is improved or
enhanced, if the patient belongs to a subgroup of patients that has a statistically significant longer
mean survival time as compared to another up of patients.
The term "progression-free survival" refers to the length of time during and after treatment
during which, according to the assessment of the treating physician or investigator, the patient's
disease does not become worse, i.e., does not progress. As the skilled person will appreciate, a
patient's progression-free al is improved or enhanced if the patient s to a subgroup
of patients that has a longer length of time during which the disease does not progress as
compared to the average or mean progression free survival time of a control group of similarly
situated patients.
The term "pharmaceutical composition" refers to a sterile preparation that is in such form as to
permit the biological ty of the medicament to be effective, and which contains no additional
components that are unacceptably toxic to a subject to which the ation would be
administered.
2. Detailed Embodiments
In the present invention, rs7993418 SNP in the VEGFR-1 gene was identified as markers or
predictive biomarkers for overall survival (OS) and/or progression-free survival (PFS) to
treatment with an angiogenesis inhibitor. The terms "marker" and "predictive biomarker" can be
used hangeably and refer to ic allele variants of genes. The variation or marker may
also be referred to as a single nucleotide polymorphism (SNP). ce information on the
SNP as well as an amino acid and nucleic acid of VEGFR-1 is available on the NCBI website
using respective reference/accession numbers, e.g.. rs7993418, NP_002010 and NM_002019.
Sequence information of rs7993418 is further shown in Table 1. In the context of the present
invention, the term “VEGFR-1” also asses variants and/or ms thereof.
Table 1
mRNA
ID Allele Sequence
Codon
ATGAACTTGAAAGCATTTAC[A/G]TATCTAATGAA
418 A/G C
GAAACAGAAAGAAT (SEQ ID NO:1)
In accordance with the methods of the present invention, SNPs of VEGFR-1 were analysed using
the samples derived from two Phase III trials with bevacizumab, i.e. AVITA (pancreatic cancer,
see, Van Cutsem, J. Clin. Oncol. 2009 27:2231-2237) and AVOREN (renal cancer, see, Escudier
et al., Lancet 2007 370:2103).
As shown in the es, the 418 SNP in VEGFR-1 was identified as the functional
variant underling the association between the VEGFR-1 locus represented by four tagging SNPs,
i.e. rs9554316, rs9582036, rs9513070 and rs9554320, and PFS and OS in bevacizumab-treated
patients from AVITA. Further, 418 correlated with PFS in bevacizumab-treated patients
in AVOREN (per-allele HR=1.8, P=0.033). No effect was seen in placebo subjects (per-allele
HR=0.8, P=0.49), suggesting that 418 can serve as a predictive marker for favourable
outcome with bevacizumab treatment.
Accordingly, the present invention provides an in vitro method of determining whether a patient
suffering from cancer is suitably treated by a therapy with an angiogenesis inhibitor sing
bevacizumab or an antibody that binds essentially the same epitope on VEGF as zumab,
said method comprising:
(a) determining in a sample d from a patient suffering from cancer the genotype at
the synonymous T/C SNP located in exon 28 of VEGFR-1 corresponding respectively to TAT
codon and TAC codon for tyrosine at position 1213, and
(b) fying said patient as more or less suitably treated by a therapy with an
angiogenesis inhibitor comprising bevacizumab or an antibody that binds essentially the same
epitope on VEGF as bevacizumab based on said genotype, wherein the presence of each T allele
at said SNP indicates an increased likelihood that the patient is more suitably treated, or the
presence of each C allele at said SNP indicates an increased likelihood that the patient is less
suitably treated. Also described is such a method which further comprises treating the patient by
the therapy with an angiogenesis inhibitor.
More specifically, the present invention provides an in vitro method of determining whether a
patient is suitably treated by a therapy with an angiogenesis inhibitor comprising bevacizumab or
an antibody that binds ially the same epitope on VEGF as zumab, said method
comprising:
(a) determining in a sample derived from a patient suffering from cancer the genotype at
the synonymous T/C SNP d in exon 28 of VEGFR-1 corresponding respectively to TAT
codon and TAC codon for tyrosine at position 1213, and
(b) identifying said patient as more or less suitably treated by a therapy with an
angiogenesis inhibitor sing bevacizumab or an antibody that binds essentially the same
epitope on VEGF as bevacizumab based on said genotype, wherein the presence of TT or TC
pe at said SNP indicates an increased likelihood that the patient is more suitably treated
than a patient having CC pe at said SNP, or the presence of CC genotype at said SNP
tes an increased likelihood that the patient is less suitably treated than a patient having TT
or TC genotype at said SNP, or
(b’) identifying a patient as more or less suitably treated by a therapy with an
enesis inhibitor comprising bevacizumab or an antibody that binds essentially the same
epitope on VEGF as bevacizumab based on said genotype, wherein the presence of TT genotype
at said SNP indicates an increased likelihood that the patient is more suitably d than a
patient having TC or CC genotype at said SNP, or the presence of TC or CC pe at said
SNP indicates an increased likelihood that the patient is less suitably treated than a patient
having TT genotype at said SNP. Also described is such a method which r comprises
treating the patient by the therapy with an angiogenesis inhibitor.
Also bed herein is a pharmaceutical ition comprising an angiogenesis inhibitor
comprising bevacizumab or an antibody that binds essentially the same epitope on VEGF as
bevacizumab for the treatment of a patient suffering from cancer, wherein the patient has been
identified as more suitably treated with the angiogenesis inhibitor by an invitro method
comprising:
(a) determining in a sample derived from a patient suffering from cancer the genotype at
the synonymous T/C SNP located in exon 28 of VEGFR-1 corresponding respectively to TAT
codon and TAC codon for tyrosine at position 1213, and
(b) identifying said patient as more or less suitably treated by a therapy with an
angiogenesis inhibitor comprising bevacizumab or an antibody that binds essentially the same
epitope on VEGF as bevacizumab based on said genotype, wherein the presence of each T allele
at said SNP indicates an increased likelihood that the patient is more suitably treated, or the
presence of each C allele at said SNP indicates an increased likelihood that the patient is less
ly treated.
Also bed herein is a pharmaceutical composition comprising an angiogenesis inhibitor that
comprises bevacizumab or an antibody that binds essentially the same epitope on VEGF as
bevacizumab, for the treatment of a patient in need thereof, n the t has been
identified as more le treated with the angiogenesis inhibitor by an in vitro method
comprising:
(a) determining in a sample derived from a patient suffering from cancer the genotype at
the mous T/C SNP located in exon 28 of VEGFR-1 corresponding respectively to TAT
codon and TAC codon for tyrosine at position 1213, and
(b) identifying said patient as more or less suitably treated by a therapy with an
angiogenesis inhibitor comprising bevacizumab or an antibody that binds essentially the same
epitope on VEGF as bevacizumab based on said genotype, wherein the presence of TT or TC
genotype at said SNP indicates an increased hood that the patient is more suitably treated
than a patient having CC genotype at said SNP, or the presence of CC genotype at said SNP
tes an increased likelihood that the patient is less suitably treated than a patient having TT
or TC genotype at said SNP, or
(b’) identifying a patient as more or less suitably treated by a therapy with an
angiogenesis inhibitor comprising zumab or an antibody that binds essentially the same
e on VEGF as bevacizumab based on said genotype, wherein the presence of TT genotype
at said SNP indicates an increased likelihood that the t is more suitably d than a
patient having TC or CC genotype at said SNP, or the presence of TC or CC genotype at said
SNP indicates an increased likelihood that the patient is less suitably d than a t
having TT genotype at said SNP.
Also described herein is a method for improving the treatment effect of a chemotherapeutic
agent or chemotherapy regimen of a patient suffering from cancer by adding an angiogenesis
inhibitor sing zumab or an dy that binds essentially the same epitope on
VEGF as bevacizumab, said method comprising:
(a) determining in a sample derived from a patient suffering from cancer the genotype at
the synonymous T/C SNP located in exon 28 of VEGFR-1 corresponding respectively to TAT
codon and TAC codon for tyrosine at position 1213;
(b) identifying said patient as more suitably treated by the addition of an angiogenesis
inhibitor comprising bevacizumab or an antibody that binds essentially the same epitope on
VEGF as bevacizumab based on said genotype, wherein the ce of each T allele at said
SNP indicates an increased likelihood that the patient is more suitably treated; and
(c) stering said angiogenesis inhibitor in combination with a herapeutic
agent or chemotherapy regimen to the t identified as more suitably treated in accordance
with (b).
More specifically, described herein is a method for improving the treatment effect of a
chemotherapeutic agent or chemotherapy regimen of a patient suffering from cancer by adding
an angiogenesis inhibitor comprising bevacizumab or an antibody that binds essentially the same
epitope on VEGF as bevacizumab, said method comprising:
(a) determining in a sample derived from a patient suffering from cancer the genotype at
the mous T/C SNP located in exon 28 of VEGFR-1 corresponding respectively to TAT
codon and TAC codon for tyrosine at on 1213;
(b) identifying said patient as more or less suitably treated by a therapy with an
angiogenesis inhibitor comprising bevacizumab or an antibody that binds essentially the same
epitope on VEGF as bevacizumab based on said genotype, n the ce of TT or TC
genotype at said SNP indicates an increased hood that the t is more suitably treated
than a patient having CC genotype at said SNP, or the presence of CC genotype at said SNP
indicates an increased likelihood that the patient is less suitably treated than a patient having TT
or TC pe at said SNP, or
(b’) identifying a patient as more or less suitably treated by a therapy with an
angiogenesis inhibitor comprising bevacizumab or an antibody that binds essentially the same
epitope on VEGF as bevacizumab based on said genotype, wherein the presence of TT genotype
at said SNP indicates an increased likelihood that the patient is more suitably treated than a
patient having TC or CC genotype at said SNP, or the presence of TC or CC genotype at said
SNP indicates an increased hood that the patient is less suitably treated than a patient
having TT genotype at said SNP; and
(c) administering said angiogenesis inhibitor in combination with a herapeutic
agent or chemotherapy regimen to a t identified as more suitably treated in accordance
with (b) or (b’).
In an embodiment, whether a patient is suitably treated by a therapy with an angiogenesis
inhibitor is determined in terms of whether PFS or OS is improved, more specifically whether
PFS is improved.
In an embodiment, cancer is selected from the group consisting of colorectal cancer,
glioblastoma, renal cancer, ovarian , breast , pancreatic cancer, gastric cancer and
lung cancer, more specifically the group consisting of renal cancer and pancreatic cancer.
In an embodiment, a patient can be a patient diagnosed with physiological or pathological
angiogenic abnormalities.
In an embodiment, the angiogenesis inhibitor is administered as a co-treatment with a
chemotherapeutic agent or chemotherapy regimen. In a further embodiment, the angiogenesis
inhibitor is administered with one or more agents selected from the group consisting of taxanes
such as docetaxel and paclitaxel, interferon alpha, 5-fluorouracil, leucovorin, gemcitabine,
nib and um-based chemotherapeutic agents such as carboplatin, cisplatin and
oxaliplatin. More specifically, the angiogenesis inhibitor is stered as a co-treatment with a
chemotherapeutic agent or chemotherapy regimen selected from the group ting of
gemcitabine-erlotinib and interferon alpha. Further, the angiogenesis inhibitor may be
stered as a co-treatment with radiotherapy.
In the context of the t invention, the sample is a ical sample and may be a blood
and/or tissue sample. In an embodiment, the sample is a blood sample, more specifically a
peripheral blood sample. In the context of the present invention, the sample is a DNA sample.
The DNA sample may be germline DNA or somatic DNA, more specifically germline DNA.
In one embodiment, the genotype is determined by means of MALDI-TOF mass spectrometry.
In addition to the detailed ption of the detection of SNPs below, the following reference
provides ce for MALDI-TOF mass spectrometry-based SNP genotyping, e.g. Storm et al.,
Methods Mol. Biol. 212:241-62, 2003.
3. Detection of Nucleic Acid rphisms
Detection techniques for evaluating nucleic acids for the presence of a SNP involve procedures
well known in the field of molecular genetics. Many, but not all, of the methods involve
amplification of nucleic acids. Ample guidance for performing amplification is ed in the
art. Exemplary references include manuals such as PCR Technology: Principles and
Applications for DNA Amplification (ed. H. A. Erlich, Freeman Press, NY, N.Y., 1992); PCR
Protocols: A Guide to Methods and Applications (eds. Innis, et al., Academic Press, San Diego,
Calif., 1990); Current Protocols in Molecular Biology, Ausubel, 1994-1999, including
supplemental updates through April 2004; Sambrook & Russell, lar Cloning, A
tory Manual (3rd Ed, 2001). l methods for detection of single nucleotide
polymorphisms are disclosed in Single Nucleotide Polymorphisms: s and ols, Pui-
Yan Kwok, ed., 2003, Humana Press.
Although the methods typically employ PCR steps, other amplification protocols may also be
used. Suitable amplification methods include ligase chain reaction (see, e.g., Wu & Wallace,
Genomics 4:560-569, 1988); strand displacement assay (see, e.g. Walker et al., Proc. Natl. Acad.
Sci. USA 89:392-396, 1992; U.S. Pat. No. 5,455,166); and several transcription-based
amplification systems, including the s described in U.S. Pat. Nos. 990; 5,409,818;
and 5,399,491; the transcription amplification system (TAS) (Kwoh et al., Proc. Natl. Acad. Sci.
USA 86:1173-1177, 1989); and self-sustained sequence replication (3SR) (Guatelli et al., Proc.
Natl. Acad. Sci. USA 87:1874-1878, 1990; WO 92/08800). Alternatively, methods that amplify
the probe to detectable levels can be used, such as Qβ-replicase amplification (Kramer & Lizardi,
Nature 339:401-402, 1989; Lomeli et al., Clin. Chem. 35:1826-1831, 1989). A review of known
amplification methods is ed, for example, by Abramson and Myers in Current n in
Biotechnology 4:41-47, 1993.
Detection of the genotype, haplotype, SNP, atellite or other polymorphism of an
individual can be med using oligonucleotide primers and/or probes. Oligonucleotides can
be prepared by any le , usually chemical synthesis. Oligonucleotides can be
synthesized using commercially available reagents and instruments. Alternatively, they can be
purchased through commercial sources. Methods of synthesizing oligonucleotides are well
known in the art (see, e.g, Narang et al., Meth. Enzymol. 99, 1979; Brown et al., Meth.
Enzymol. 68:109-151, 1979; Beaucage et al., Tetrahedron Lett. 22:1859-1862, 1981; and the
solid support method of U.S. Pat. No. 4,458,066). In addition, modifications to the abovedescribed
methods of synthesis may be used to desirably impact enzyme behavior with respect to
the sized oligonucleotides. For example, incorporation of modified phosphodiester
linkages (e.g., phosphorothioate, methylphosphonates, phosphoamidate, or boranophosphate) or
linkages other than a phosphorous acid derivative into an oligonucleotide may be used to prevent
cleavage at a ed site. In addition, the use of 2’-amino modified sugars tends to favor
displacement over digestion of the oligonucleotide when ized to a nucleic acid that is also
the template for synthesis of a new nucleic acid strand.
The genotype of an individual can be determined using many detection methods that are well
known in the art. Most assays entail one of several general ols: hybridization using allelespecific
oligonucleotides, primer ion, allele-specific ligation, sequencing, or
electrophoretic separation techniques, e.g., single-stranded conformational polymorphism (SSCP)
and heteroduplex is. Exemplary assays include 5’-nuclease assays, template-directed dyeterminator
incorporation, molecular beacon allele-specific oligonucleotide assays, single-base
extension assays, and SNP scoring by real-time pyrophosphate sequences. is of amplified
sequences can be performed using various logies such as microchips, fluorescence
polarization assays, and MALDI-TOF (matrix assisted laser desorption ionization-time of flight)
mass spectrometry. Two methods that can also be used are assays based on invasive cleavage
with Flap nucleases and methodologies ing k probes.
Determination of the presence or absence of a particular allele is generally performed by
analyzing a nucleic acid sample that is obtained from the individual to be ed. Often, the
nucleic acid sample comprises genomic DNA. The genomic DNA is typically obtained from
blood samples, but may also be obtained from other cells or tissues.
It is also possible to e RNA samples for the presence of polymorphic alleles. For example,
mRNA can be used to determine the genotype of an individual at one or more rphic sites.
In this case, the nucleic acid sample is obtained from cells in which the target nucleic acid is
expressed, e.g., adipocytes. Such an analysis can be performed by first e-transcribing the
target RNA using, for example, a viral reverse transcriptase, and then amplifying the ing
cDNA; or using a combined high-temperature reverse-transcription-polymerase chain reaction
(RT-PCR), as described in U.S. Pat. Nos. 5,310,652; 5,322,770; 058; 5,641,864; and
,693,517.
Frequently used methodologies for analysis of nucleic acid samples to detect SNPs are briefly
described. However, any method known in the art can be used in the invention to detect the
presence of single nucleotide substitutions.
a. Allele-Specific Hybridization
This que, also commonly referred to as allele specific oligonucleotide ization (ASO)
(e.g., Stoneking et al., Am. J. Hum. Genet. 48:70-382, 1991; Saiki et al., Nature 324, 163-166,
1986; EP 235,726; and WO 89/11548), relies on guishing between two DNA molecules
differing by one base by hybridizing an oligonucleotide probe that is specific for one of the
variants to an amplified product obtained from amplifying the nucleic acid sample. This method
typically employs short oligonucleotides, e.g. 15-20 bases in length. The probes are designed to
differentially hybridize to one variant versus another. Principles and guidance for designing such
probe is available in the art, e.g. in the references cited herein. Hybridization conditions should
be sufficiently stringent that there is a icant difference in hybridization intensity between
alleles, and producing an ially binary se, whereby a probe hybridizes to only one of
the alleles. Some probes are designed to hybridize to a segment of target DNA such that the
polymorphic site aligns with a central position (e.g., in a 15-base oligonucleotide at the 7
position; in a 16-based ucleotide at either the 8 or 9 position) of the probe, but this design
is not required.
The amount and/or presence of an allele is determined by measuring the amount of allelespecific
oligonucleotide that is hybridized to the sample. Typically, the ucleotide is labeled
with a label such as a fluorescent label. For example, an allele-specific oligonucleotide is applied
to immobilized oligonucleotides representing SNP sequences. After stringent hybridization and
washing conditions, fluorescence intensity is measured for each SNP oligonucleotide.
In one embodiment, the nucleotide present at the polymorphic site is fied by hybridization
under sequence-specific hybridization conditions with an oligonucleotide probe or primer
y complementary to one of the polymorphic alleles in a region encompassing the
polymorphic site. The probe or primer hybridizing ce and sequence-specific hybridization
conditions are ed such that a single mismatch at the polymorphic site destabilizes the
hybridization duplex sufficiently so that it is effectively not formed. Thus, under ce-
specific hybridization conditions, stable duplexes will form only between the probe or primer
and the exactly complementary c sequence. Thus, oligonucleotides from about 10 to about
nucleotides in length, usually from about 15 to about 35 nucleotides in length, which are
exactly complementary to an allele sequence in a region which encompasses the polymorphic
site are within the scope of the invention.
In an alternative embodiment, the nucleotide present at the polymorphic site is identified by
ization under sufficiently ent hybridization conditions with an oligonucleotide
substantially complementary to one of the SNP alleles in a region encompassing the polymorphic
site, and exactly complementary to the allele at the polymorphic site. Because mismatches which
occur at non-polymorphic sites are mismatches with both allele sequences, the difference in the
number of mismatches in a duplex formed with the target allele sequence and in a duplex formed
with the corresponding non-target allele sequence is the same as when an oligonucleotide exactly
complementary to the target allele sequence is used. In this embodiment, the hybridization
conditions are d sufficiently to allow the formation of stable duplexes with the target
sequence, while maintaining sufficient stringency to de the formation of stable duplexes
with non-target ces. Under such sufficiently stringent hybridization conditions, stable
duplexes will form only between the probe or primer and the target allele. Thus, oligonucleotides
from about 10 to about 35 nucleotides in length, usually from about 15 to about 35 nucleotides in
length, which are substantially mentary to an allele sequence in a region which
encompasses the polymorphic site, and are exactly mentary to the allele sequence at the
polymorphic site, are within the scope of the invention.
The use of substantially, rather than exactly, complementary oligonucleotides may be desirable
in assay formats in which optimization of hybridization conditions is limited. For example, in a
typical multi-target immobilized-oligonucleotide assay format, probes or primers for each target
are immobilized on a single solid support. Hybridizations are carried out simultaneously by
contacting the solid support with a solution containing target DNA. As all izations are
carried out under cal conditions, the hybridization ions cannot be separately
optimized for each probe or . The incorporation of mismatches into a probe or primer can
be used to adjust duplex stability when the assay format des adjusting the hybridization
conditions. The effect of a particular introduced mismatch on duplex stability is well known, and
the duplex stability can be routinely both estimated and empirically determined, as described
above. Suitable hybridization conditions, which depend on the exact size and sequence of the
probe or primer, can be selected empirically using the guidance provided herein and well known
in the art. The use of oligonucleotide probes or primers to detect single base pair differences in
sequence is described in, for e, Conner et al., 1983, Proc. Natl. Acad. Sci. USA 80:278-
282, and U.S. Pat. Nos. 5,468,613 and 5,604,099, each incorporated herein by nce.
The proportional change in stability between a perfectly matched and a single-base mismatched
ization duplex depends on the length of the hybridized oligonucleotides. Duplexes formed
with shorter probe sequences are destabilized proportionally more by the presence of a mismatch.
Oligonucleotides between about 15 and about 35 nucleotides in length are often used for
sequence-specific detection. Furthermore, e the ends of a hybridized oligonucleotide
undergo continuous random dissociation and re-annealing due to thermal energy, a mismatch at
either end destabilizes the hybridization duplex less than a mismatch occurring internally. For
discrimination of a single base pair change in target sequence, the probe sequence is selected
which izes to the target sequence such that the polymorphic site occurs in the interior
region of the probe.
The above criteria for selecting a probe sequence that hybridizes to a specific allele apply to the
hybridizing region of the probe, i.e., that part of the probe which is involved in hybridization
with the target sequence. A probe may be bound to an additional nucleic acid sequence, such as a
poly-T tail used to immobilize the probe, t significantly altering the hybridization
teristics of the probe. One of skill in the art will recognize that for use in the present
methods, a probe bound to an additional c acid sequence which is not complementary to
the target sequence and, thus, is not involved in the hybridization, is essentially equivalent to the
unbound probe.
Suitable assay formats for detecting hybrids formed between probes and target nucleic acid
sequences in a sample are known in the art and include the immobilized target (dot-blot) format
and immobilized probe (reverse ot or line-blot) assay formats. Dot blot and reverse dot blot
assay formats are described in U.S. Pat. Nos. 5,310,893; 5,451,512; 5,468,613; and 5,604,099;
each incorporated herein by nce.
In a dot-blot format, amplified target DNA is immobilized on a solid support, such as a nylon
membrane. The membrane-target complex is incubated with labeled probe under suitable
hybridization conditions, unhybridized probe is removed by washing under suitably ent
conditions, and the membrane is monitored for the presence of bound probe.
In the reverse dot-blot (or line-blot) format, the probes are immobilized on a solid support, such
as a nylon ne or a microtiter plate. The target DNA is d, typically during
amplification by the incorporation of labeled primers. One or both of the primers can be labeled.
The membrane-probe complex is incubated with the labeled amplified target DNA under suitable
hybridization conditions, unhybridized target DNA is removed by g under suitably
stringent conditions, and the membrane is monitored for the presence of bound target DNA. A
reverse line-blot detection assay is described in the example.
An allele-specific probe that is specific for one of the polymorphism variants is often used in
conjunction with the allele-specific probe for the other polymorphism variant. In some
ments, the probes are immobilized on a solid support and the target ce in an
individual is analyzed using both probes simultaneously. Examples of nucleic acid arrays are
described by WO 95/11995. The same array or a different array can be used for analysis of
characterized polymorphisms. WO 95/11995 also describes ays that are zed for
detection of variant forms of a pre-characterized polymorphism. Such a subarray can be used in
detecting the presence of the polymorphisms described herein.
b. Allele-Specific Primers
Polymorphisms are also commonly detected using allele-specific amplification or primer
extension methods. These reactions typically involve use of primers that are designed to
specifically target a polymorphism via a ch at the 3’-end of a primer. The presence of a
mismatch effects the y of a polymerase to extend a primer when the polymerase lacks error-
correcting activity. For example, to detect an allele sequence using an allele-specific
amplification- or extension-based , a primer complementary to one allele of a
polymorphism is designed such that the 3’-terminal tide hybridizes at the polymorphic
position. The presence of the particular allele can be determined by the ability of the primer to
initiate extension. If the 3’-terminus is mismatched, the ion is impeded.
In some embodiments, the primer is used in conjunction with a second primer in an amplification
reaction. The second primer hybridizes at a site unrelated to the polymorphic position.
Amplification proceeds from the two primers leading to a detectable product signifying the
particular allelic form is present. Allele-specific amplification- or extension-based methods are
described in, for e, WO 93/22456; U.S. Pat. Nos. 5,137,806; 5,595,890; 5,639,611; and
U.S. Pat. No. 4,851,331.
Using allele-specific amplification-based ping, identification of the alleles requires only
detection of the ce or absence of amplified target sequences. Methods for the detection of
amplified target sequences are well known in the art. For example, gel electrophoresis and probe
hybridization assays described are often used to detect the presence of nucleic acids.
In an alternative probe-less method, the amplified c acid is detected by monitoring the
increase in the total amount of double-stranded DNA in the on mixture, is described, e.g. in
U.S. Pat. No. 5,994,056; and European Patent Publication Nos. 487,218 and 512,334. The
ion of double-stranded target DNA relies on the increased fluorescence various DNA-
binding dyes, e.g., SYBR Green, exhibit when bound to double-stranded DNA.
As iated by one in the art, allele-specific amplification methods can be performed in
reaction that employ multiple allele-specific primers to target particular s. Primers for such
multiplex ations are generally labeled with distinguishable labels or are selected such that
the amplification products produced from the alleles are distinguishable by size. Thus, for
example, both alleles in a single sample can be identified using a single ication by gel
analysis of the amplification product.
As in the case of allele-specific , an allele-specific oligonucleotide primer may be y
complementary to one of the polymorphic alleles in the hybridizing region or may have some
mismatches at positions other than the 3’-terminus of the oligonucleotide, which mismatches
occur at non-polymorphic sites in both allele sequences.
c. Detectable Probes
i) 5’-Nuclease Assay Probes
Genotyping can also be performed using a “ TaqMan®” or “ 5’-nuclease assay” , as
described in U.S. Pat. Nos. 5,210,015; 5,487,972; and 5,804,375; and Holland et al., 1988, Proc.
Natl. Acad. Sci. USA 88:7276-7280. In the TaqMan® assay, labeled detection probes that
hybridize within the ied region are added during the amplification reaction. The probes are
modified so as to prevent the probes from acting as primers for DNA synthesis. The
amplification is performed using a DNA polymerase having 5’- to 3’-exonuclease activity.
During each synthesis step of the amplification, any probe which hybridizes to the target nucleic
acid downstream from the primer being ed is degraded by the 5’- to 3’-exonuclease
activity of the DNA polymerase. Thus, the synthesis of a new target strand also s in the
degradation of a probe, and the lation of degradation product provides a measure of the
synthesis of target sequences.
The hybridization probe can be an allele-specific probe that discriminates between the SNP
alleles. Alternatively, the method can be performed using an allele-specific primer and a labeled
probe that binds to amplified product.
Any method suitable for detecting degradation t can be used in a 5’-nuclease assay. Often,
the ion probe is d with two fluorescent dyes, one of which is capable of quenching
the fluorescence of the other dye. The dyes are attached to the probe, usually one attached to the
’-terminus and the other is attached to an internal site, such that quenching occurs when the
probe is in an unhybridized state and such that cleavage of the probe by the 5’- to 3’-exonuclease
ty of the DNA rase occurs in between the two dyes. Amplification results in
cleavage of the probe between the dyes with a concomitant elimination of ing and an
increase in the scence observable from the initially quenched dye. The accumulation of
degradation product is monitored by measuring the increase in reaction fluorescence. U.S. Pat.
Nos. 5,491,063 and 5,571,673, both incorporated herein by nce, describe alternative
methods for detecting the degradation of probe which occurs concomitant with amplification.
ii) Secondary Structure Probes
Probes detectable upon a ary ural change are also suitable for detection of a
polymorphism, including SNPs. Exemplified secondary structure or stem-loop structure probes
include molecular beacons or Scorpion® primer/probes. Molecular beacon probes are singlestranded
oligonucleic acid probes that can form a hairpin structure in which a phore and a
quencher are usually placed on the opposite ends of the oligonucleotide. At either end of the
probe short complementary sequences allow for the formation of an intramolecular stem, which
enables the phore and the quencher to come into close proximity. The loop portion of the
molecular beacon is complementary to a target nucleic acid of interest. Binding of this probe to
its target nucleic acid of interest forms a hybrid that forces the stem apart. This causes a
conformation change that moves the fluorophore and the quencher away from each other and
leads to a more intense fluorescent signal. Molecular beacon probes are, however, highly
sensitive to small ce variation in the probe target (Tyagi S. and Kramer F. R., Nature
Biotechnology, Vol. 14, pages 303-308 (1996); Tyagi et al., Nature Biotechnology, Vol. 16,
pages 49-53(1998); Piatek et al., Nature hnology, Vol. 16, pages 359-363 (1998); Marras
S. et al., Genetic Analysis: Biomolecular Engineering, Vol. 14, pages 151-156 (1999); Tpp I. et
al, BioTechniques, Vol 28, pages 732-738 (2000)). A Scorpion® primer/probe comprises a stemloop
structure probe covalently linked to a primer.
d. DNA Sequencing and Single Base Extensions
SNPs can also be detected by direct sequencing. Methods include e.g. dideoxy sequencing-based
methods and other s such as Maxam and Gilbert sequence (see, e.g. Sambrook and
Russell, supra).
Other detection methods include Pyrosequencing™ of oligonucleotide-length products. Such
methods often employ amplification techniques such as PCR. For example, in pyrosequencing, a
sequencing primer is hybridized to a single stranded, PCR-amplified, DNA template; and
incubated with the enzymes, DNA polymerase, ATP sulfurylase, luciferase and apyrase, and the
substrates, ine 5’ phosphosulfate (APS) and luciferin. The first of four deoxynucleotide
triphosphates (dNTP) is added to the reaction. DNA polymerase catalyzes the incorporation of
the deoxynucleotide triphosphate into the DNA , if it is complementary to the base in the
template strand. Each incorporation event is accompanied by release of pyrophosphate (PPi) in a
quantity lar to the amount of incorporated nucleotide. ATP sulfurylase quantitatively
converts PPi to ATP in the presence of adenosine 5’ phosphosulfate. This ATP drives the
luciferase-mediated conversion of rin to oxyluciferin that generates visible light in amounts
that are proportional to the amount of ATP. The light produced in the luciferase-catalyzed
reaction is detected by a charge coupled device (CCD) camera and seen as a peak in a
Pyrogram™. Each light signal is tional to the number of nucleotides incorporated.
Apyrase, a nucleotide degrading enzyme, continuously degrades unincorporated dNTPs and
excess ATP. When degradation is te, another dNTP is added.
Another r method for characterizing SNPs does not require use of a complete PCR, but
typically uses only the extension of a primer by a single, fluorescence-labeled
dideoxyribonucleic acid molecule (ddNTP) that is complementary to the nucleotide to be
investigated. The nucleotide at the polymorphic site can be identified via detection of a primer
that has been extended by one base and is fluorescently labeled (e.g., Kobayashi et al, Mol. Cell.
Probes, 9:175-182, 1995).
e. Electrophoresis
Amplification ts ted using the rase chain reaction can be analyzed by the
use of denaturing nt gel electrophoresis. Different alleles can be fied based on the
different sequence-dependent melting properties and electrophoretic migration of DNA in
solution (see, e.g. Erlich, ed., PCR Technology, Principles and ations for DNA
Amplification, W. H. Freeman and Co, New York, 1992, Chapter 7).
Distinguishing of microsatellite polymorphisms can be done using capillary electrophoresis.
Capillary electrophoresis conveniently allows identification of the number of repeats in a
particular microsatellite allele. The application of capillary electrophoresis to the analysis of
DNA polymorphisms is well known to those in the art (see, for example, Szantai, et al, J
Chromatogr A. (2005) 1079(1-2):41-9; im and Ekstrom, Electrophoresis (2005)
26(13):2520-30 and Mitchelson, Mol Biotechnol. (2003) 24(1):41-68).
f. Single-Strand Conformation Polymorphism Analysis
Alleles of target sequences can be differentiated using -strand conformation polymorphism
analysis, which identifies base differences by alteration in electrophoretic migration of single
ed PCR products, as described, e.g, in Orita et al., Proc. Nat. Acad. Sci. 86, 2766-2770
(1989). Amplified PCR products can be generated as described above, and heated or otherwise
red, to form single stranded amplification products. Single-stranded nucleic acids may
refold or form secondary ures which are partially ent on the base sequence. The
different electrophoretic mobilities of single-stranded amplification products can be related to
base-sequence difference between alleles of target
SNP detection methods often employ labeled oligonucleotides. Oligonucleotides can be labeled
by incorporating a label able by spectroscopic, photochemical, biochemical,
immunochemical, or chemical means. Useful labels include fluorescent dyes, radioactive labels,
e.g. 32P, electron-dense ts, enzyme, such as peroxidase or alkaline phosphatase, biotin, or
haptens and ns for which antisera or monoclonal antibodies are available. Labeling
ques are well known in the art (see, e.g. t Protocols in Molecular Biology, supra;
Sambrook & Russell, supra).
4. Methods of Treatment
Dosages of with bevacizumab (Avastin®) for treatments of specific cancers, according to the
EMEA, are as follows. For metastatic carcinoma of the colon or rectum (mCRC) recommended
dosages are 5 mg/kg or 10 mg/kg of body weight given once every 2 weeks or 7.5 mg/kg or 15
mg/kg of body weight given once every 3 weeks, for atic breast cancer (mBC)
ended dosages are 10 mg/kg of body weight given once every 2 weeks or 15 mg/kg of
body weight given once every 3 weeks as an intravenous on, and for non-small cell lung
cancer (NSCLC) recommended dosages are 7.5 mg/kg or 15 mg/kg of body weight given once
every 3 weeks as an intravenous infusion. al t in NSCLC ts has been
demonstrated with both 7.5 mg/kg and 15 mg/kg doses. For details refer to section 5.1
Pharmacodynamic Properties, Non-small cell lung cancer (NSCLC). For advanced and/or
metastatic Renal Cell Cancer (mRCC) preferred dosages are 10 mg/kg of body weight given
once every 2 weeks as an intravenous infusion(in addition to um-based chemotherapy for
up to 6 cycles of treatment followed by zumab (Avastin®) as a single agent until disease
progression). For gliablastoma a particular dosage is 10 mg/kg every 2 weeks.
In the context of the present ion, the angiogenesis inhibitor may be administered in
addition to or as a co-therapy or a co-treatment with one or more chemotherapeutic agents
administered as part of standard chemotherapy regimen as known in the art. Examples of agents
included in such standard herapy regimens include 5-fluorouracil, leucovorin, irinotecan,
gemcitabine, erlotinib, capecitabine, taxanes, such as docetaxel and paclitaxel, interferon alpha,
vinorelbine, and platinum-based chemotherapeutic , such as paclitaxel, carboplatin,
cisplatin and oxaliplatin. Examples of co-treatments for metastatic pancreatic cancer include
gemcitabine-erlotinib plus bevacizumab at a dosage of 5mg/kg or 10 mg/kg of body weight
given once every two weeks or 7.5 mg/kg or 15 mg/kg of body weight given once every three
weeks. Examples of co-treatments for renal cell cancer include interferon alpha plus
bevacizumab at a dosage of or 10 mg/kg of body weight given once every two weeks. Further, a
patient may be co-treated with a combination of irinotecan, 5-fluorouracil, leucovorin, also
referred to as IFL, as, for example, a IFL, with a combination of oxaliplatin, orin,
and 5-fluorouracil, also referred to a FOLFOX4 regimen, or with a combination of capecitabine
and oxaliplatin, also referred to as XELOX. Accordingly, in a further embodiment of the
invention, the patient suffering from a malignant disease or a disease involving physiological and
pathological angiogenesis is being treated with one or more chemotherapeutic agents such as
-fluorouracil, leucovorin, irinotecan, abine-erlotinib, capecitabine and/or platinum-based
chemotherapeutic agents, such as paclitaxel, carboplatin and oxaliplatin. Examples of co-
therapy or co-treatment include 5 mg/kg bevacizumab (Avastin®) every two week with bolus-
IFL or 10 mg/kg bevacizumab (Avastin®) every 2 weeks with FOLFOX4 for metastatic
colorectal , 15 mg/kg bevacizumab (Avastin®) every 3 weeks with caboplatis/paclitaxel
for non-squamous all cell lung cancer, and 10 mg/kg bevacizumab (Avastin®) every 2
weeks with axel for metastatic breast cancer. r, the angiogenesis inhibitor to be
administered may be administered as a rapy or a atment with radiotherapy.
. Kit
Also bed herein is a diagnostic ition or kit comprising any of the mentioned
oligonucleotides and optionally suitable means for detection.
The kit described herein may advantageously be used for carrying out a method of the invention
and could be, inter alia, employed in a variety of applications, e.g., in the diagnostic field or as a
ch tool. The parts of the kit can be packages individually in vials or in combination in
containers or multicontainer units. Manufacture of the kit follows preferably standard procedures
which are known to the person skilled in the art. The kit or diagnostic compositions may be used
for detection of the one or more variant alleles in accordance with the herein-described methods
of the invention, employing, for example, amplification techniques as bed herein.
Also described herein is a kit useful for carrying out the methods herein described, comprising
oligonucleotides or polynucleotides capable of determining the genotype of one or more SNPs.
The oligonucleotides or polynucleotides may comprise primers and/or probes.
The present invention is further described by reference to the following non-limited figures and
examples as well as with specific reference to Examples 1 and 2 and Figures 1
to 16 of .
Examples
PATIENTS AND METHODS
Study design
AVITA (BO17706) and AVOREN (BO17705) were enter, randomized phase III trials that
respectively included 607 patients with metastatic pancreatic adenocarcinoma and 649 patients
with metastatic renal cell carcinoma. In AVITA, patients were randomly assigned to receive
gemcitabine–erlotinib plus bevacizumab (n=306) or placebo (n=301). In AVOREN, patients
were ly assigned to e interferon alfa-2a plus bevacizumab (n=327) or placebo
(n=322). s of these studies have been described:
- AVITA: Van Cutsem et al. Phase III trial of bevacizumab in combination with gemcitabine and
erlotinib in patients with metastatic pancreatic . J. Clinc. Oncol. 27, 2231-7 (2009)
- AVOREN: Escudier B, Pluzanska A, wski P, Ravaud A, Bracarda S, ik C, et al.
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a
randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103-2111.
Trial protocols and genetic ker studies were approved by the institutional review board at
each site and were conducted in accordance with the Declaration of Helsinki, current US Food
and Drug Administration Good Clinical Practices, and local ethical and legal requirements. All
patients included in the biomarker studies provided separate written informed consent for c
biomarker testing. Blood samples for these analyses were collected before study treatment began.
Single nucleotide polymorphism selection
The following genes in the VEGF signaling cascade were selected: the VEGF ligand, the VEGF
homologs (placenta growth factor [PlGF], VEGF-B, VEGF-C, and VEGF-D [also known as c-
fos-induced growth factor or FlGF]), VEGF receptor-2 (VEGFR-2 or KDR) and VEGF receptor-
1 (VEGFR-1 or FLT1), regulators of hypoxia (hypoxia-inducible factor-1α ], HIF-2α
[EPAS1], the factor inhibiting HIF-1α , the von Hippel–Lindau tumor suppressor [VHL],
the histone acetyltransferase EP300), and the oxygen sensors l hydroxylase domaincontaining
protein-1, -2, and -3 [EGLN-2, -1, and -3], respectively). Genomic sequences up to
5kb upstream of the ation start site and downstream of the 3’-poly-A-adenylation site of
each gene were used to select SNPs from the HapMap database (release 24/phase II). Tagging
SNPs were ed using the Tagger (Pe'er I, de Bakker PI, Maller J, Yelensky R, Altshuler D,
Daly MJ. Evaluating and improving power in whole-genome association s using fixed
marker sets. Nat Genet 2006;38:663-7) provided in the HAPLOVIEW software package (Barrett
JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps.
Bioinformatics 2005;21:263-5). Only common SNPs, i.e. with minor allele frequency (f)≥0.1
and r2 threshold >0.8, were considered. In total, 140 tagging SNPs were selected using these
criteria. Additionally, 14 SNPs located in exonic ces and inducing non-synonymous
amino acid changes at a frequency f≥0.1 were selected from the dbSNP database, as were
additional SNPs in VEGF (rs699947, rs833061, rs2010963, and rs3025039), VEGFR-1
458691) and VEGFR-2 (rs2071559), which were previously reported to affect function or
sion of these genes. With future analyses in mind, 24 SNPs known to increase
susceptibility to hypertension and thrombosis were also included in the design. In total, 184
SNPs were thus selected for genotyping.
Genotyping
Peripheral blood was sampled in K2EDTA Vacutainer® tubes and germline DNA was extracted
from the precipitated leukocyte cell fraction. Genotyping was carried out in a d manner at
the Vesalius Research Center (Leuven, Belgium) with MassARRAY® iPLEX Gold (Sequenom
Inc, San Diego, CA, USA). SNPs that failed in the first ping round were redesigned using
a ent set of polymerase chain reaction primers and ed. The 27 SNPs that also failed
the second design were considered failures. Overall, 157 SNPs ) were successfully
genotyped with an overall success rate of 98.5% in AVITA. DNA samples from AVOREN and
functional tion studies were genotyped for a limited set of SNPs ing rs7993418,
rs9554320, rs9582036, rs9554316, and rs9513070 using RAY®.
Statistics
Nineteen SNPs occurred at a frequency f≤0.1 in AVITA and were therefore excluded from
further analysis. Hardy–Weinberg equilibrium was assessed for the remaining 138 SNPs using a
standard χ2 with one degree of freedom. No major violations were detected. Linkage
ilibrium (LD) strength was evaluated with r2 and Lewontin's D’ statistic using the
Haploview software package (Broad Institute, Cambridge, MA, USA). Associations between
SNP genotypes and time to event outcomes (PFS and OS) were first evaluated using the Cox
proportional hazards method according to an additive genetic model. OS analysis was performed
separately for each of the 138 SNPs in the bevacizumab arm only. The significance threshold for
an overall type I error rate of 0.05 was set at P<0.00036 based on the Bonferroni correction for
multiple comparison in AVITA. Significant SNPs identified in this step were r analyzed
considering a threshold of P<0.05 and using a Cox regression analysis: (i) in the bevacizumab
arm only, while adjusting for other baseline prognostic covariates; (ii) in the placebo arm only, to
assess whether observed associations were ndent of treatment, and (iii) in both treatment
groups, to assess genotype by treatment interaction. A stepwise model selection approach was
applied to the subgroup available for genetic ker analysis in order to fy a set of
baseline covariates affecting treatment outcome. The selected variables used as adjustment
covariates were: neutrophil count, C-reactive protein, and tumor on. The association of
rs7993418 was replicated in AVOREN considering a old of P<0.05 and using Cox
regression analyses similar to AVITA.
RESULTS
AVITA study teristics
Blood samples from AVITA were available from 160 out of 607 patients (26.4%); 6 patients
were Asian and 154 were ian. Since SNP frequencies differ between ethnic groups, only
DNA specimens from Caucasian patients were analyzed. The genetic biomarker subgroup was
comparable with the full patient cohort with respect to age and gender distribution, smoking
status, OS and PFS (Table 2). The median OS in the subgroup was 7.4 and 6.7 months in the
bevacizumab and placebo arms, respectively 9), and median PFS was 5.3 and 4.1 months,
respectively (p=0.078).
Table 2. AVITA patient demographics and clinical characteristics at baseline
Demographics and al characteristics are given for the full AVITA trial cohort and for the
subgroup available for genetic biomarker analysis. Bev denotes bevacizumab; CI confidence
interval, GE gemcitabine–erlotinib, mo months.
AVITA population Biomarker subgroup
Characteristic GE Bev+GE GE Bev+GE
(N=301) (N=306) (N=77) (N=77)
Sex — no. (%)
Female 113 (38) 132 (43) 25 (32) 29 (37)
Male 188 (62) 174 (57) 52 (68) 48 (62)
Age category — no. (%)
<65 yr 194 (64) 182 (59) 50 (65) 45 (58)
≥65 yr 107 (36) 124 (41) 27 (35) 32 (42)
Smoking status — no. (%)
Current smoker 63 (21) 50 (16) 18 (23) 14 (18)
Past smoker 99 (33) 104 (34) 36 (47) 32 (42)
Never smoker 137 (46) 151 (49) 22 (29) 31 (40)
Unknown 2 (<1) 1 (<1) 1 (1) 0 (0)
Karnofsky performance status— no. (%)
60 11 (4) 12 (4) 2 (3) 2 (3)
70 26 (9) 28 (9) 5 (6) 6 (8)
80 71 (24) 78 (25) 14 (18) 20 (26)
90 120 (40) 119 (39) 37 (48) 30 (39)
100 73 (24) 69 (23) 19 (25) 19 (25)
Visual analogue scale score for pain — no. (%)
<20 137 (61) 162 (64) 50 (75) 47 (67)
≥20 89 (39) 91 (36) 17 (25) 23 (33)
Progression-free survival
Patients with event — no. (%) 295 (98.0) 295 (96.4) 76 (98.7) 72 (93.5)
Patients without event — no. (%) 6 (2.0) 11 (3.6) 1 (1.3) 5 (6.5)
Median time to event — 3.6 (3.4–3.7) 4.6 (3.8–5.4) 4.1 (3.5–5.3) 5.3 (4.0–7.0)
mo (95% CI)
Hazard ratio (95% CI) 0.74 (0.64–0.87) 0.75 (1.03–0.54)
Overall al
Patients with event — no. (%) 277 (92.0) 276 (90.2) 75 (97.4) 69 (89.6)
ts without event — no. (%) 24 (8.0) 30 (9.8) 2 (2.6) 8 (10.4)
Median time to event — 6.1 (5.5–6.8) 7.2 (6.6– 6.7 (5.3; 8.9) 7.4 (6.1; 9.9)
mo (95% CI) 8.0)
Hazard ratio (95% CI) 0.89 (0.76–1.05) 0.80 (1.12–0.58)
The rs9582036 SNP in VEGFR-1 correlates with bevacizumab treatment outcome
Of all 138 SNPs, only the 036 SNP in 1 passed the P value old adjusted for
multiple testing. The overall effect of this SNP on OS was significant in the zumab arm
(per-allele HR=2.1, 014) and consistent with an additive risk effect model (Fig. 3 of WO
2011/015348). Median OS increased from 4.8 months and 6.0 months in CC and AC carriers,
respectively, to 10.3 months in AA carriers. After adjustment for neutrophil count, C-reactive
protein level and tumor location, the association of rs9582036 with OS in the bevacizumab arm
was slightly attenuated but still significant (HR=1.9, P=0.002). Subsequent Cox regression
analysis for rs9582036 in the placebo arm did not show a statistically significant ation
between OS and SNP genotypes (Fig. 4 of ). A formal test of interaction
between rs9582036 and treatment (bevacizumab or o) was tically significant
(P=0.041), ting that rs9582036 was a predictive marker for treatment outcome in AVITA.
Cox regression analysis also revealed a correlation between rs9582036 and PFS in the
bevacizumab arm (per-allele HR=1.89, P=0.00081; Fig. 5 of ). No such effect
for PFS was observed in the placebo arm (P=0.58; Fig. 6 of ).
Associated SNPs define a locus in the VEGFR-1 TK domain
Three other SNPs in VEGFR-1 (rs9554316, rs9513070, and rs9554320) also correlated with OS
in the bevacizumab arm, but did not pass the P value threshold adjusted for multiple testing
(P=0.00042, 81, and 97, respectively). The predictive effects of these SNPs were
r to those of rs9582036 (Figures 7 to 10 of ). All four SNPs were located
close to each other, i.e. in introns 25, 27, 28, and 29 for rs9554320, 036, rs9554316, and
rs9513070, respectively, and represented four consecutive regions of high linkage disequilibrium
within VEGFR-1. When considering the P value of every SNP as a me asure of its association
with OS and plotting these values as a function of the location of the SNP in VEGFR-1, an
association signal encompassing exons 25 to 29, which code for amino acid residues 1029 to
1272 in the TK domain, was observed in the bevacizumab arm. As expected, no such signal was
observed in the placebo group.
Fine-mapping of the 1 locus
To identify all SNPs located in 1, we used whole-genome sequencing data from 60
Caucasian HapMap samples in the 1000 Genomes project (CEU population, Release July 2010;
www.1000genomes.org). Using the VCF Tools version 0.1.5, SNPs in the coding region of
VEGFR-1 and in the 15kb up- and downstream sequence (i.e., the 27763000-27982000
Ensembl 36.3 coordinates) were ed. In total, we identified 628 SNPs, of which 381 had a
minor allele frequency (MAF) ≥0.05. Using the Haploview 4.2 software, we identified 48 SNPs
that were in LD with one of the four tagging SNPs associated with treatment outcome after
bevacizumab in AVITA (i.e., rs9582036, rs9554316, rs9513070 and rs9554320). The threshold
for LD was set at r2≥0.12 as this was the lowest r2 between one of the four tag SNPs in the
samples analyzed (Table 3).
Table 3
r2 value rs9513070 rs9554316 rs9582036 rs9554320
rs9513070 - 0.28 0.21 0.12
rs9554316 0.28 - 0.67 0.33
rs9582036 0.21 0.67 - 0.48
rs9554320 0.12 0.33 0.48 -
The se linkage disequilibrium between the 4 tagging SNPs in the VEGFR-1 locus is shown.
SNPs, which are in perfect correlation and are completely mous, have a r2 value of 1.
SNPs with an r2 value of 0 occur independently from each other.
To identify which of these 48 SNPs affect VEGFR-1 function and causally contribute to
treatment outcome after bevacizumab, we used the ite (Reumers J, Conde L, Medina I, et
al. Joint annotation of coding and non-coding single tide polymorphisms and ons in
the SNPeffect and PupaSuite databases. Nucleic Acids Res 2008;36:D825-9) and AnnoVar
(Wang K, Li M, Hakonarson H. ANNOVAR: functional tion of genetic variants from
high-throughput cing data. c Acids :e164) tools. In particular, we assessed
which of these SNPs were located in coding regions, transcription factor binding sites, exonic
splicing enhancers/silencers or miRNA binding sites, or in other evolutionary conserved
sequence s. Only one SNP was located in one of the VEGFR-1 exons, i.e., rs7993418 was
d in exon 28 of VEGFR-1. Two SNPs (i.e., rs9513071 and rs7982283) were loc ated in a
predicted CCCTC-binding factor (CTCF) binding motif, but were unlikely to functionally affect
VEGFR-1 function since they did not disrupt the core-binding domain of the CTCF motif. Five
other SNPs were located on conserved positions, which were defined as conservation of the
respective nucleotide position in at least 10 s out of the 44 species in the database. These
SNPs were located downstream of the VEGFR-1 gene (rs9554309), in intronic sequences
(rs9513073, rs9551471, rs7992940) and in exon 28 of VEGFR-1 (rs7993418). No other relevant
SNPs were identified. Notably, of these 5 SNPs, 418 showed the highest degree of LD
with the four tag SNPs in the VEGFR-1 TK locus (r2 values of 0.34, 0.83, 0.67 and 0.36 for LD
with rs9513070, rs9554316, rs9582036 and rs9554320, respectively). Overall, based on this finemapping
and in silico analysis, 418 was considered to be the SNP with the t
potential to affect VEGFR-1 function. Rs7993418 is a mous T/C SNP located in exon 28
of VEGFR-1 that changes the TAT codon of tyrosine 1213 into a TAC codon (Tyr1213Tyr) and
is located in the ype block of rs9554316.
The rs7993418 variant functionally affects VEGFR-1 expression
1. In vitro transcription/translation of VEGFR-1 cDNA constructs
To demonstrate that rs7993418 functionally affects VEGFR-1 expression, its effect on
transcription and translation of VEGFR-1 cDNA was assessed in vitro using the rabbit
reticulocyte lysate system. Two versions of the VEGFR-1 cDNA, carrying either the TAT or
TAC codon for Tyr1213, were generated. Both cDNAs were cloned into the pcDNA3 expression
vector and were used for in vitro transcription/translation using the commercial TnT T7 Quickcoupled
rabbit reticulocyte lysate kit (Promega, Cat# L1170). ength VEGFR-1 cDNA
carrying either the wild-type TAT or mutant TAC codon yielded equal s of transcribed
mRNA but different amounts of translated VEGFR-1 protein. In particular, a 27% increase in
VEGFR-1 protein was ed for TAC versus TAT-carrying cDNA constructs (P<0.001).
Likewise, transient overexpression in HEK293T cells confirmed that, although VEGFR-1 mRNA
expression was equal between cells expressing the TAC and TAT-carrying construct, up to 15%
more VEGFR-1 protein was translated by TAC-expressing cells (P<0.001). Expression of the
e VEGFR-1 isoform (sVEGFR-1) produced by proteolytic cleavage of full-length
transmembrane VEGFR-1 (tmVEGFR-1) was similarly increased in cells expressing the TAC-
carrying construct (P<0.001).
2. -1 expression levels in human plasma
Furthermore, since R-1 and sVEGFR-1 protein levels are strongly correlated and
sVEGFR-1 can easily be assessed in human plasma, -1 plasma levels were measured in
two ndent cohorts and stratified for rs7993418. Plasma was collected from 369 healthy
individuals of Flemish ancestry via the Red Cross (Leuven, Belgium) and DNA from these
individuals was genotyped for 418. We compared sVEGFR-1 plasma levels from 30 and
28 randomly selected TT and TC carriers against each of the 11 CC (mutant) carriers via the
Human Soluble VEGF -1 assay (R&D systems, catalog # DVR100B). We
observed that CC carriers have an 18% increased median VEGFR-1 expression compared to TT
and TC rs (P=0.006). y ANOVA was used to te the effect of rs7993418 on
sVEGFR-1 sion; a two-sided P value <0.05 was ered statistically significant. We
replicated this association in an independent cohort of plasma samples from breast cancer
patients (collected at the Leuven Multidisciplinary Breast Center). Briefly, DNA from 263
patients was genotyped for rs7993418 and sVEGFR-1 plasma levels from 23 and 27 randomly
selected TT (wildtype) and TC rs was compared against each of the 9 detected CC (mutant)
carriers. A similar increase in sVEGFR-1 expression (19%) was noticed in CC carriers versus TT
and TC carriers (P=0.014). One-way ANOVA was used to evaluate the effect of rs7993418 on
sVEGFR-1 expression; a two-sided P value <0.05 was considered statistically significant.
3. VEGFR-1 expression in HUVECs stratified for rs7993418 genotypes
y, by comparing HUVECs that carry rs7993418 TT, TC and CC genotypes, we could not
identify any differences for tmVEGFR-1 0) and sVEGFR-1 1) mRNA expression
levels. r, similar to the in vitro translation experiments, these HUVECs showed slightly
increased tmVEGFR-1 protein expression levels for CC carriers versus TT or TC carriers (23%
increase; 9). Similar effects between CC versus TC or TT carriers were observed for
sVEGFR-1 (39% increase; P=0.044).
4. ERK1/2 activation upon PlGF stimulation
The above findings te that rs7993418, by enhancing mRNA translation efficacy, increases
expression of tmVEGFR-1 and sVEGFR-1. Furthermore, as expected by the increase in
VEGFR-1 expression, HUVEC cultures homozygous for the C-allele exhibited increased
downstream 1 signaling upon activation with the selective VEGFR-1 ligand, PlGF.
This is shown by increased levels of phospho-ERK1 and phospho-ERK2 in CC versus TT
rs7993418 carriers (2.0 versus 1.6 fold induction for phospho-ERK1 and 2.1 versus 1.4 fold
induction for phospho-ERK2; P=0.045 and P=0.046; n=3 versus 5). ERK1 and ERK2
phosphorylation was measured using the Phospho-MAPK array kit (R&D systems).
Phosphorylated proteins were detected using the Pierce ECL chemiluminescent substrate
(Thermo Scientific) and blots were developed using Scientific imaging film ). Blots were
scanned and intensities were quantified using the ImageJ 1.43 software. Intensities were
background corrected and scaled relative to the internal positive control of the Phospho-MAPK
array kit. Experiments were performed twice and average values of both experiments are shown.
Since the Human Phospho-MAPK array kit does not correct for the total amount of ERK1 or 2,
we measured total ERK1/2 concentrations using SureFire technology (Perkin Elmer). Total
ERK1/2 levels were similar for TT and CC carriers under ulated and stimulated conditions
(P=0.2 and 0.34, respectively).
Association of the 1 locus replicates in AVOREN
Finally, in an attempt to replicate the association of the VEGFR-1 locus with bevacizumab
treatment outcome, we investigated a second phase III al study involving metastatic renal
cell carcinoma patients (AVOREN). Blood samples from AVOREN were available from 110 out
of 649 patients (16.9%), 59 of which received bevacizumab (Table 4).
Table 4. AVOREN patient aphics and clinical characteristics at baseline
Demographics and characteristics are given for the full AVOREN trial cohort and for the
subgroup available for genetic biomarker analysis. Bev denotes bevacizumab; CI confidence
al, IFN Interferon alfa-2a, mo .
AVOREN population Biomarker subgroup
Characteristic IFN Bev+IFN IFN Bev+IFN
(N=322) (N=327) (N=51) (N=59)
Sex — no. (%)
Female 87 (27) 105 (32) 13 (25) 29 (29)
Male 235 (73) 222 (68) 38 (75) 48 (71)
Age category — no. (%)
<65 yr 204 (63) 206 (63) 30 (59) 37 (63)
≥65 yr 118 (37) 121 (37) 21 (41) 22 (37)
Smoking status — no. (%)
Current smoker 43 (13) 45 (14) 9 (18) 6 (10)
Past smoker 129 (40) 126 (39) 20 (39) 23 (39)
Never smoker 148 (46) 154 (47) 22 (43) 30 (51)
Unknown 2 (<1) 2 (<1) 0 (0) 0 (0)
ssion-free al
Patients with event — no. (%) 298 (92.5) 301 (92.0) 42 (82.4) 56 (94.9)
Patients without event — no. (%) 24 (7.5) 26 (8.0) 9 (17.6) 3 (5.1)
Median time to event — 5.5 (4.2–5.7) 10.2 (7.7– 8.7 (7.2– 15.5 (13.5–
mo (95% CI) 11.1) 14.2) 18.4)
Hazard ratio (95% CI) 0.75 (0.64–0.88) 0.93 (0.62–1.40)
Overall survival
Patients with event — no. (%) 224 (69.6) 220 (67.3) 28 (54.9) 30 (50.8)
Patients without event — no. (%) 98 (30.4) 107 (32.7) 23 (45.1) 29 (49.2)
Median time to event — 21.3 (18.4– 23.3 (20.4– 37.2 (28.2– 34.9 (30.0–.)
mo (95% CI) 24.5) 27.0) 39.7)
Hazard ratio (95% CI) 0.91 (0.76–1.10) 0.93 (0.55–1.55)
A similar SNP analysis as for the AVITA trial, as described above, was performed on the genetic
samples from patients in the AVOREN trial. Since AVOREN patients receiving zumab
switched to heterogeneous second-line therapies upon disease progression, we only assessed
correlation to PFS. Although the c biomarker subgroup was characterized by a longer PFS
than the full patient cohort, rs7993418 correlated with PFS in the bevacizumab llele
HR=1.8, P=0.033, Table 5), but not in the placebo arm (per-allele HR=0.8, P=0.49).
Table 5. –Meier estimates of PFS in bevacizumab and o d groups in
AVOREN, according to rs7993418, rs9554316 and 070 genotype.
Progression-Free Survival
Median time to event — mo
IFN Bev+IFN
Genotype
(N=51) (N=59)
rs7993418 or rs9554316*
TT 7.95 (N=26) 16.66 (N=36)
TC 13.37 (N=17) 10.15 (N=18)
CC 8.11 (N=2) 14.52 (N=1)
Hazard ratio (95% CI) 0.83 (0.47 – 1.44) 1.81 (1.08 – 3.05)
P value 0.49 0.033
Bev denotes bevacizumab; CI confidence interval, IFN Interferon alfa-2a, mo months.
* Rs7993418 and rs9554316 were synonymous to each other and the analysis in Table 5 was
conducted on rs9554316.
In Table 5, the CC genotype of rs7993418 involves only one patient; therefore, no conclusion
can be drawn about the median survival of CC carries. Nevertheless, the combined genotypic
effect by both TC and CC carriers of rs7993418 in AVOREN is tically significant
(P=0.033). The results shown in Table 5 together with the described functional
characterization of rs7993418 support the findings of the present invention that the C allele
adversely affects the survival in bevacizumab-treated patients by increasing expression of
VEGFR-1, which could amplify the well-recognized phenomenon of compensatory angiogenesis
driven by the PlGF ligand.
l, this indicates that the VEGFR-1 locus may also be predictive for zumab treatment
outcome in renal cell carcinoma patients.
A genetic locus in the VEGFR-1 TK domain that is associated with PFS and OS in atic
pancreatic cancer patients (AVITA) has been identified in the present invention and replicated
with PFS in renal cell carcinoma patients (AVOREN). Importantly, this association was specific
for patients receiving bevacizumab as no significant s were observed in placebo-treated
patients. We also validated this locus at the functional level by demonstrating that rs7993418
enhances VEGFR-1 mRNA translation efficacy, leading to increased expression of VEGFR-1
protein.
Concerning how increased VEGFR-1 expression could contribute to reduced zumab
treatment outcome, it is well known that activation of VEGFR-1 triggers angiogenesis, either
directly by transmitting intracellular s or indirectly by transphosphorylation of VEGFR-2,
ing in increased VEGFRdriven angiogenesis. Interestingly, tumors that overexpress the
VEGFR-1 selective ligand, PlGF, grow less rapidly in mice lacking the VEGFR-1 TK domain as
a result of reduced vascularization of these tumors. Since PlGF levels are also increased in
patients treated with bevacizumab, a c locus that amplifies downstream signaling of
VEGFR-1 could render the vasculature more dependent on PlGF and cause resistance to anti-
VEGF treatment. Similarly, increased -1 levels can sequester tumor-derived VEGF,
thereby reducing its pro-angiogenic effects transduced via VEGFR-2 and limiting the benefits of
VEGF lization h bevacizumab. , Mazzone et al. have shown that high
tmVEGFR-1 and sVEGFR-1 expressing endothelial cells contribute to tumor vasculature
normalization, in part because these cells are less responsive to the mitogenic and migratory
ty of VEGF (Mazzone M, Dettori D, Leite de Oliveira R, et al. Heterozygous deficiency of
PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell
2009;136:839-51). ably, rectal cancer patients with increased plasma sVEGFR-1
expression before and during treatment have a reduced benefit from bevacizumab, thereby
underscoring the observations of the present invention about the potential value of VEGFR-1 as a
biomarker of bevacizumab ent (Duda DG, et al. Plasma soluble VEGFR-1 is a potential
dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally
advanced rectal cancer. Oncologist. 2010;15(6):577-83)
At first glance, it may seem surprising that a synonymous SNP affects VEGFR-1 expression
without changing the amino acid ce. However, synonymous mutations have previously
been reported to affect n expression and have already been implicated in >40 diseases. One
potential mechanism whereby synonymous SNPs may affect protein sion is through codon
bias. In particular, the rs7993418 variant may affect codon usage of the tyrosine located on
position 1213 in the TK domain of VEGFR-1. This domain is characterized by a strong bias
s TAC codons, i.e. 16 TAC codons versus 5 TAT codons, which both code for a tyrosine.
Such codon bias is also present in highly expressed genes across various s, in which it
represents a ism to promote efficient translation of highly expressed genes. More
efficient VEGFR-1 translation d by the TAC codon can be achieved through s
mechanisms, including i) the more favorable interaction of the TAC codon with its tRNA
anticodon due to the stronger G-C hydrogen bond interaction at the third codon position
(Grosjean H, Fiers W. Preferential codon usage in prokaryotic genes: the optimal codon-
don interaction energy and the selective codon usage in efficiently expressed genes. Gene
1982;18:199-209), ii) increased availability of tRNAs for the TAC codon (the TAT tRNA is
encoded by only a single gene, whereas 14 tRNA genes exist for TAC) (Juhling F, Morl M,
Hartmann RK, Sprinzl M, Stadler PF, Putz J. tRNAdb 2009: compilation of tRNA sequences and
tRNA genes. Nucleic Acids Res 2009;37:D159-62), and iii) the effect of ‘tRNA recycling’ by
ribosomes, which favors re-use of the most frequently-used codon to e translation
efficacy (Cannarozzi G, Schraudolph NN, Faty M, et al. A role for codon order in translation
dynamics. Cell;141:355-67). All er, these isms support the notion that codon bias
mediates the effect of rs7993418 on VEGFR-1 expression and its association with treatment
outcome of bevacizumab.
Claims (12)
1. An in vitro method of determining whether a patient suffering from cancer or physiological or pathological angiogenic abnormalities is suitably treated by a therapy with an enesis inhibitor comprising bevacizumab or an antibody that binds essentially the same 5 epitope on VEGF as bevacizumab, said method comprising: (a) determining in a sample derived from a patient suffering from cancer or physiological or pathological angiogenic abnormalities the genotype at the synonymous T/C SNP located in exon 28 of VEGFR-1 corresponding respectively to TAT codon and TAC codon for tyrosine at position 1213, and 10 (b) identifying said patient as more or less suitably treated by a therapy with an enesis inhibitor sing bevacizumab or an dy that binds essentially the same epitope on VEGF as bevacizumab based on said genotype, n the ce of each T allele at said SNP indicates an increased likelihood that the patient is more suitably treated, or the ce of each C allele at said SNP indicates an increased likelihood that the patient is less 15 ly treated.
2. The method of claim 1, wherein whether a patient is suitably treated by a therapy with an enesis inhibitor is determined in termes of whether progression-free survival or overall survival is improved.
3. The method of any one of claims 1 to 2, wherein the therapy comprises the angiogenesis tor and a chemotherapeutic agent or herapy regimen.
4. The method of any one of claims 1 to 3, wherein the therapy comprises the 25 angiogenesis inhibitor and one or more agents selected from the group consisting of taxanes, interferon alpha, 5-fluorouracil, capecitabine, leucovorin, gemcitabine, erlotinib and platinumbased chemotherapeutic agents.
5. The method of any one of claims 1 to 4, wherein the cancer is atic cancer, 30 renal cell cancer, colorectal cancer, breast cancer or lung cancer.
6. The use of a pharmaceutical composition comprising bevacizumab for the preparation of a medicament for the treatment of a patient suffering from cancer or physiological or pathological angiogenic abnormalities, wherein the patient has been identified as more suitably treated with bevacizumab in accordance with the method of any one of claims 1 to 5.
7. The use of an angiogenesis inhibitor comprising zumab or an antibody that 5 binds essentially the same epitope on VEGF as bevacizumab for the preparation of a medicament for improving the ent effect of a chemotherapeutic agent or chemotherapy regimen of a patient ing from cancer or physiological or pathological angiogenic abnormalities, wherein the t has been identified by a method comprising: (a) determining in a sample derived from a patient suffering from cancer or physiological 10 or pathological enic abnormalities the genotype at the synonymous T/C SNP located in exon 28 of VEGFR-1 ponding respectively to TAT codon and TAC codon for tyrosine at position 1213; and (b) identifying said patient as more suitably treated by the addition of an angiogenesis inhibitor comprising zumab or an antibody that binds essentially the same epitope on 15 VEGF as bevacizumab based on said genotype, wherein the ce of each T allele at said SNP indicates an increased likelihood that the patient is more suitably treated.
8. The use of claim 7, wherein whether a patient is suitably treated by a therapy with an angiogenesis tor is determined in terms of whether ssion-free survival or overall 20 survival is improved.
9. The use of any one of claims 7 to 8, wherein the chemotherapeutic agent comprises one or more agents selected from the group consisting of taxanes, interferon alpha, 5- fluorouracil, capecitabine, leucovorin, gemcitabine, erlotinib and platinum-based 25 chemotherapeutic agents.
10. The use of any one of claims 7 to 9, wherein the cancer is pancreatic cancer, renal cell cancer, colorectal cancer, breast cancer or lung cancer. 30
11. An in vitro method according to any one of claims 1 to 3 substantially as herein described with reference to any example thereof.
12. The use according to any one of claims 6 to 10 substantially as herein described with nce to any example thereof. case 30723_
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11190229.2 | 2011-11-23 | ||
EP11190229 | 2011-11-23 | ||
PCT/EP2012/072953 WO2013076029A1 (en) | 2011-11-23 | 2012-11-19 | Responsiveness to angiogenesis inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ624442A NZ624442A (en) | 2016-07-29 |
NZ624442B2 true NZ624442B2 (en) | 2016-11-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7727724B2 (en) | Polymorphisms in voltage-gated sodium channel α 1-subunit as markers for therapy selection | |
US20170066822A1 (en) | Responsiveness to angiogenesis inhibitors | |
AU2016203889A1 (en) | Responsiveness to angiogenesis inhibitors | |
JP2020120625A (en) | Risk assessment method for non-alcoholic liver disease using single nucleotide polymorphism | |
US20140294768A1 (en) | Responsiveness to angiogenesis inhibitors | |
US8323896B2 (en) | Epidermal growth factor (EGF) expression and/or polymorphisms thereof for predicting the risk of developing cancer | |
EP2751280B1 (en) | Method for predicting risk of hypertension associated with anti-angiogenesis therapy | |
NZ624442B2 (en) | Responsiveness to angiogenesis inhibitors | |
NZ620345B2 (en) | Responsiveness to angiogenesis inhibitors | |
AU2010281043B8 (en) | Responsiveness to angiogenesis inhibitors | |
NZ620343B2 (en) | Method for predicting risk of hypertension associated with anti-angiogenesis therapy | |
WO2013172922A1 (en) | Lmtk3 genotype analysis for use in predicting outcome and therapy selection |